Title,Authors,Abstract,Published Year,Published Month,Journal,Volume,Issue,Pages,Accession Number,DOI,Ref,Covidence #,Study,Notes,Tags
Region-based analysis of rare genomic variants in whole-genome sequencing datasets reveal two novel Alzheimer's disease-associated genes: DTNB and DLG2.,Prokopenko D.; Lee S.; Hecker J.; Mullin K.; Morgan S.; Katsumata Y.;  .; Weiner MW.; Fardo DW.; Laird N.; Bertram L.; Hide W.; Lange C.; Tanzi RE.,"Alzheimer's disease (AD) is a genetically complex disease for which nearly 40 loci have now been identified via genome-wide association studies (GWAS). We attempted to identify groups of rare variants (alternate allele frequency <0.01) associated with AD in a region-based, whole-genome sequencing (WGS) association study (rvGWAS) of two independent AD family datasets (NIMH/NIA; 2247 individuals; 605 families). Employing a sliding window approach across the genome, we identified several regions that achieved association p values <10-6, using the burden test or the SKAT statistic. The genomic region around the dystobrevin beta (DTNB) gene was identified with the burden and SKAT test and replicated in case/control samples from the ADSP study reaching genome-wide significance after meta-analysis (pmeta = 4.74 × 10-8). SKAT analysis also revealed region-based association around the Discs large homolog 2 (DLG2) gene and replicated in case/control samples from the ADSP study (pmeta = 1 × 10-6). In conclusion, in a region-based rvGWAS of AD we identified two novel AD genes, DLG2 and DTNB, based on association with rare variants.",2022,04,Molecular psychiatry,27,4,1963-1969,,10.1038/s41380-022-01475-0,35246634,#1613,Prokopenko 2022,"",""
Identification of Novel Alzheimer's Disease Loci Using Sex-Specific Family-Based Association Analysis of Whole-Genome Sequence Data.,Prokopenko D.; Hecker J.; Kirchner R.; Chapman BA.; Hoffman O.; Mullin K.; Hide W.; Bertram L.; Laird N.; DeMeo DL.; Lange C.; Tanzi RE.,"With the advent of whole genome-sequencing (WGS) studies, family-based designs enable sex-specific analysis approaches that can be applied to only affected individuals; tests using family-based designs are attractive because they are completely robust against the effects of population substructure. These advantages make family-based association tests (FBATs) that use siblings as well as parents especially suited for the analysis of late-onset diseases such as Alzheimer's Disease (AD). However, the application of FBATs to assess sex-specific effects can require additional filtering steps, as sensitivity to sequencing errors is amplified in this type of analysis. Here, we illustrate the implementation of robust analysis approaches and additional filtering steps that can minimize the chances of false positive-findings due to sex-specific sequencing errors. We apply this approach to two family-based AD datasets and identify four novel loci (GRID1, RIOK3, MCPH1, ZBTB7C) showing sex-specific association with AD risk. Following stringent quality control filtering, the strongest candidate is ZBTB7C (Pinter = 1.83 × 10-7), in which the minor allele of rs1944572 confers increased risk for AD in females and protection in males. ZBTB7C encodes the Zinc Finger and BTB Domain Containing 7C, a transcriptional repressor of membrane metalloproteases (MMP). Members of this MMP family were implicated in AD neuropathology.",2020,03,Scientific reports,10,1,5029,,10.1038/s41598-020-61883-6,32193444,#1644,Prokopenko 2020,"",""
Whole-genome sequencing reveals new Alzheimer's disease-associated rare variants in loci related to synaptic function and neuronal development.,Prokopenko D.; Morgan SL.; Mullin K.; Hofmann O.; Chapman B.; Kirchner R.;  .; Amberkar S.; Wohlers I.; Lange C.; Hide W.; Bertram L.; Tanzi RE.,"Genome-wide association studies have led to numerous genetic loci associated with Alzheimer's disease (AD). Whole-genome sequencing (WGS) now permits genome-wide analyses to identify rare variants contributing to AD risk. We performed single-variant and spatial clustering-based testing on rare variants (minor allele frequency [MAF] ≤1%) in a family-based WGS-based association study of 2247 subjects from 605 multiplex AD families, followed by replication in 1669 unrelated individuals. We identified 13 new AD candidate loci that yielded consistent rare-variant signals in discovery and replication cohorts (4 from single-variant, 9 from spatial-clustering), implicating these genes: FNBP1L, SEL1L, LINC00298, PRKCH, C15ORF41, C2CD3, KIF2A, APC, LHX9, NALCN, CTNNA2, SYTL3, and CLSTN2. Downstream analyses of these novel loci highlight synaptic function, in contrast to common AD-associated variants, which implicate innate immunity and amyloid processing. These loci have not been associated previously with AD, emphasizing the ability of WGS to identify AD-associated rare variants, particularly outside of the exome.",2021,09,Alzheimer's & dementia : the journal of the Alzheimer's Association,17,9,1509-1527,,10.1002/alz.12319,33797837,#1623,Prokopenko 2021,"",""
Genetic data and cognitively defined late-onset Alzheimer's disease subgroups.,Mukherjee S.; Mez J.; Trittschuh EH.; Saykin AJ.; Gibbons LE.; Fardo DW.; Wessels M.; Bauman J.; Moore M.; Choi SE.; Gross AL.; Rich J.; Louden DKN.; Sanders RE.; Grabowski TJ.; Bird TD.; McCurry SM.; Snitz BE.; Kamboh MI.; Lopez OL.; De Jager PL.; Bennett DA.; Keene CD.; Larson EB.;  .;  .;  .;  .;  .;  .; Crane PK.,"Categorizing people with late-onset Alzheimer's disease into biologically coherent subgroups is important for personalized medicine. We evaluated data from five studies (total n = 4050, of whom 2431 had genome-wide single-nucleotide polymorphism (SNP) data). We assigned people to cognitively defined subgroups on the basis of relative performance in memory, executive functioning, visuospatial functioning, and language at the time of Alzheimer's disease diagnosis. We compared genotype frequencies for each subgroup to those from cognitively normal elderly controls. We focused on APOE and on SNPs with p < 10-5 and odds ratios more extreme than those previously reported for Alzheimer's disease (<0.77 or >1.30). There was substantial variation across studies in the proportions of people in each subgroup. In each study, higher proportions of people with isolated substantial relative memory impairment had ≥1 APOE ε4 allele than any other subgroup (overall p = 1.5 × 10-27). Across subgroups, there were 33 novel suggestive loci across the genome with p < 10-5 and an extreme OR compared to controls, of which none had statistical evidence of heterogeneity and 30 had ORs in the same direction across all datasets. These data support the biological coherence of cognitively defined subgroups and nominate novel genetic loci.",2020,11,Molecular psychiatry,25,11,2942-2951,,10.1038/s41380-018-0298-8,30514930,#1586,Mukherjee 2020,"",""
Family history aggregation unit-based tests to detect rare genetic variant associations with application to the Framingham Heart Study.,Wang Y.; Chen H.; Peloso GM.; Meigs JB.; Beiser AS.; Seshadri S.; DeStefano AL.; Dupuis J.,"A challenge in standard genetic studies is maintaining good power to detect associations, especially for low prevalent diseases and rare variants. The traditional methods are most powerful when evaluating the association between variants in balanced study designs. Without accounting for family correlation and unbalanced case-control ratio, these analyses could result in inflated type I error. One cost-effective solution to increase statistical power is exploitation of available family history (FH) that contains valuable information about disease heritability. Here, we develop methods to address the aforementioned type I error issues while providing optimal power to analyze aggregates of rare variants by incorporating additional information from FH. With enhanced power in these methods exploiting FH and accounting for relatedness and unbalanced designs, we successfully detect genes with suggestive associations with Alzheimer disease, dementia, and type 2 diabetes by using the exome chip data from the Framingham Heart Study.",2022,04,American journal of human genetics,109,4,738-749,,10.1016/j.ajhg.2022.03.001,35316615,#1611,Wang 2022,"",""
A Fast and Accurate Method for Genome-Wide Time-to-Event Data Analysis and Its Application to UK Biobank.,Bi W.; Fritsche LG.; Mukherjee B.; Kim S.; Lee S.,"With increasing biobanking efforts connecting electronic health records and national registries to germline genetics, the time-to-event data analysis has attracted increasing attention in the genetics studies of human diseases. In time-to-event data analysis, the Cox proportional hazards (PH) regression model is one of the most used approaches. However, existing methods and tools are not scalable when analyzing a large biobank with hundreds of thousands of samples and endpoints, and they are not accurate when testing low-frequency and rare variants. Here, we propose a scalable and accurate method, SPACox (a saddlepoint approximation implementation based on the Cox PH regression model), that is applicable for genome-wide scale time-to-event data analysis. SPACox requires fitting a Cox PH regression model only once across the genome-wide analysis and then uses a saddlepoint approximation (SPA) to calibrate the test statistics. Simulation studies show that SPACox is 76-252 times faster than other existing alternatives, such as gwasurvivr, 185-511 times faster than the standard Wald test, and more than 6,000 times faster than the Firth correction and can control type I error rates at the genome-wide significance level regardless of minor allele frequencies. Through the analysis of UK Biobank inpatient data of 282,871 white British European ancestry samples, we show that SPACox can efficiently analyze large sample sizes and accurately control type I error rates. We identified 611 loci associated with time-to-event phenotypes of 12 common diseases, of which 38 loci would be missed within a logistic regression framework with a binary phenotype defined as event occurrence status during the follow-up period.",2020,08,American journal of human genetics,107,2,222-233,,10.1016/j.ajhg.2020.06.003,32589924,#1577,Bi 2020,"",""
A novel age-informed approach for genetic association analysis in Alzheimer's disease.,Le Guen Y.; Belloy ME.; Napolioni V.; Eger SJ.; Kennedy G.; Tao R.; He Z.; Greicius MD.;  .,"Many Alzheimer's disease (AD) genetic association studies disregard age or incorrectly account for it, hampering variant discovery. Using simulated data, we compared the statistical power of several models: logistic regression on AD diagnosis adjusted and not adjusted for age; linear regression on a score integrating case-control status and age; and multivariate Cox regression on age-at-onset. We applied these models to real exome-wide data of 11,127 sequenced individuals (54% cases) and replicated suggestive associations in 21,631 genotype-imputed individuals (51% cases). Modeling variable AD risk across age results in 5-10% statistical power gain compared to logistic regression without age adjustment, while incorrect age adjustment leads to critical power loss. Applying our novel AD-age score and/or Cox regression, we discovered and replicated novel variants associated with AD on KIF21B, USH2A, RAB10, RIN3, and TAOK2 genes. Our AD-age score provides a simple means for statistical power gain and is recommended for future AD studies.",2021,04,Alzheimer's research & therapy,13,1,72,,10.1186/s13195-021-00808-5,33794991,#1624,LeGuen 2021,"",""
"Genome-wide analysis of common and rare variants via multiple knockoffs at biobank scale, with an application to Alzheimer disease genetics.",He Z.; Le Guen Y.; Liu L.; Lee J.; Ma S.; Yang AC.; Liu X.; Rutledge J.; Losada PM.; Song B.; Belloy ME.; Butler RR.; Longo FM.; Tang H.; Mormino EC.; Wyss-Coray T.; Greicius MD.; Ionita-Laza I.,"Knockoff-based methods have become increasingly popular due to their enhanced power for locus discovery and their ability to prioritize putative causal variants in a genome-wide analysis. However, because of the substantial computational cost for generating knockoffs, existing knockoff approaches cannot analyze millions of rare genetic variants in biobank-scale whole-genome sequencing and whole-genome imputed datasets. We propose a scalable knockoff-based method for the analysis of common and rare variants across the genome, KnockoffScreen-AL, that is applicable to biobank-scale studies with hundreds of thousands of samples and millions of genetic variants. The application of KnockoffScreen-AL to the analysis of Alzheimer disease (AD) in 388,051 WG-imputed samples from the UK Biobank resulted in 31 significant loci, including 14 loci that are missed by conventional association tests on these data. We perform replication studies in an independent meta-analysis of clinically diagnosed AD with 94,437 samples, and additionally leverage single-cell RNA-sequencing data with 143,793 single-nucleus transcriptomes from 17 control subjects and AD-affected individuals, and proteomics data from 735 control subjects and affected indviduals with AD and related disorders to validate the genes at these significant loci. These multi-omics analyses show that 79.1% of the proximal genes at these loci and 76.2% of the genes at loci identified only by KnockoffScreen-AL exhibit at least suggestive signal (p < 0.05) in the scRNA-seq or proteomics analyses. We highlight a potentially causal gene in AD progression, EGFR, that shows significant differences in expression and protein levels between AD-affected individuals and healthy control subjects.",2021,12,American journal of human genetics,108,12,2336-2353,,10.1016/j.ajhg.2021.10.009,34767756,#1616,He 2021,"",""
A quantitative trait rare variant nonparametric linkage method with application to age-at-onset of Alzheimer's disease.,Zhao L.; Zhang Z.; Rodriguez SMB.; Vardarajan BN.; Renton AE.; Goate AM.; Mayeux R.; Wang GT.; Leal SM.,"To analyze pedigrees with quantitative trait (QT) and sequence data, we developed a rare variant (RV) quantitative nonparametric linkage (QNPL) method, which evaluates sharing of minor alleles. RV-QNPL has greater power than the traditional QNPL that tests for excess sharing of minor and major alleles. RV-QNPL is robust to population substructure and admixture, locus heterogeneity, and inclusion of nonpathogenic variants and can be readily applied outside of coding regions. When QNPL was used to analyze common variants, it often led to loci mapping to large intervals, e.g., >40 Mb. In contrast, when RVs are analyzed, regions are well defined, e.g., a gene. Using simulation studies, we demonstrate that RV-QNPL is substantially more powerful than applying traditional QNPL methods to analyze RVs. RV-QNPL was also applied to analyze age-at-onset (AAO) data for 107 late-onset Alzheimer's disease (LOAD) pedigrees of Caribbean Hispanic and European ancestry with whole-genome sequence data. When AAO of AD was analyzed regardless of APOE ε4 status, suggestive linkage (LOD = 2.4) was observed with RVs in KNDC1 and nominally significant linkage (p < 0.05) was observed with RVs in LOAD genes ABCA7 and IQCK. When AAO of AD was analyzed for APOE ε4 positive family members, nominally significant linkage was observed with RVs in APOE, while when AAO of AD was analyzed for APOE ε4 negative family members, nominal significance was observed for IQCK and ADAMTS1. RV-QNPL provides a powerful resource to analyze QTs in families to elucidate their genetic etiology.",2020,12,European journal of human genetics : EJHG,28,12,1734-1742,,10.1038/s41431-020-0703-z,32740652,#1635,Zhao 2020,"",""
Whole-genome sequencing reveals novel ethnicity-specific rare variants associated with Alzheimer's disease.,Shigemizu D.; Asanomi Y.; Akiyama S.; Mitsumori R.; Niida S.; Ozaki K.,"Alzheimer's disease (AD) is the most common multifactorial neurodegenerative disease among elderly people. Genome-wide association studies (GWAS) have been highly successful in identifying genetic risk factors. However, GWAS investigate common variants, which tend to have small effect sizes, and rare variants with potentially larger phenotypic effects have not been sufficiently investigated. Whole-genome sequencing (WGS) enables us to detect those rare variants. Here, we performed rare-variant association studies by using WGS data from 140 individuals with probable AD and 798 cognitively normal elder controls (CN), as well as single-nucleotide polymorphism genotyping data from an independent large Japanese AD cohort of 1604 AD and 1235 CN subjects. We identified two rare variants as candidates for AD association: a missense variant in OR51G1 (rs146006146, c.815 G > A, p.R272H) and a stop-gain variant in MLKL (rs763812068, c.142 C > T, p.Q48X). Subsequent in vitro functional analysis revealed that the MLKL stop-gain variant can contribute to increases not only in abnormal cells that should die by programmed cell death but do not, but also in the ratio of Aβ42 to Aβ40. We further detected AD candidate genes through gene-based association tests of rare variants; a network-based meta-analysis using these candidates identified four functionally important hub genes (NCOR2, PLEC, DMD, and NEDD4). Our findings will contribute to the understanding of AD and provide novel insights into its pathogenic mechanisms that can be used in future studies.",2022,May,Molecular psychiatry,27,5,2554-2562,,10.1038/s41380-022-01483-0,35264725,#1612,Shigemizu 2022,"",""
Identification of putative causal loci in whole-genome sequencing data via knockoff statistics.,He Z.; Liu L.; Wang C.; Le Guen Y.; Lee J.; Gogarten S.; Lu F.; Montgomery S.; Tang H.; Silverman EK.; Cho MH.; Greicius M.; Ionita-Laza I.,"The analysis of whole-genome sequencing studies is challenging due to the large number of rare variants in noncoding regions and the lack of natural units for testing. We propose a statistical method to detect and localize rare and common risk variants in whole-genome sequencing studies based on a recently developed knockoff framework. It can (1) prioritize causal variants over associations due to linkage disequilibrium thereby improving interpretability; (2) help distinguish the signal due to rare variants from shadow effects of significant common variants nearby; (3) integrate multiple knockoffs for improved power, stability, and reproducibility; and (4) flexibly incorporate state-of-the-art and future association tests to achieve the benefits proposed here. In applications to whole-genome sequencing data from the Alzheimer's Disease Sequencing Project (ADSP) and COPDGene samples from NHLBI Trans-Omics for Precision Medicine (TOPMed) Program we show that our method compared with conventional association tests can lead to substantially more discoveries.",2021,05,Nature communications,12,1,3152,,10.1038/s41467-021-22889-4,34035245,#1620,He 2021,"",""
Exome-wide age-of-onset analysis reveals exonic variants in ERN1 and SPPL2C associated with Alzheimer's disease.,He L.; Loika Y.; Park Y.;  .; Bennett DA.; Kellis M.; Kulminski AM.;  .,"Despite recent discoveries in genome-wide association studies (GWAS) of genomic variants associated with Alzheimer's disease (AD), its underlying biological mechanisms are still elusive. The discovery of novel AD-associated genetic variants, particularly in coding regions and from APOE ε4 non-carriers, is critical for understanding the pathology of AD. In this study, we carried out an exome-wide association analysis of age-of-onset of AD with ~20,000 subjects and placed more emphasis on APOE ε4 non-carriers. Using Cox mixed-effects models, we find that age-of-onset shows a stronger genetic signal than AD case-control status, capturing many known variants with stronger significance, and also revealing new variants. We identified two novel variants, rs56201815, a rare synonymous variant in ERN1, and rs12373123, a common missense variant in SPPL2C in the MAPT region in APOE ε4 non-carriers. Besides, a rare missense variant rs144292455 in TACR3 showed the consistent direction of effect sizes across all studies with a suggestive significant level. In an attempt to unravel their regulatory and biological functions, we found that the minor allele of rs56201815 was associated with lower average FDG uptake across five brain regions in ADNI. Our eQTL analyses based on 6198 gene expression samples from ROSMAP and GTEx revealed that the minor allele of rs56201815 was potentially associated with elevated expression of ERN1, a key gene triggering unfolded protein response (UPR), in multiple brain regions, including the posterior cingulate cortex and nucleus accumbens. Our cell-type-specific eQTL analysis using ~80,000 single nuclei in the prefrontal cortex revealed that the protective minor allele of rs12373123 significantly increased the expression of GRN in microglia, and was associated with MAPT expression in astrocytes. These findings provide novel evidence supporting the hypothesis of the potential involvement of the UPR to ER stress in the pathological pathway of AD, and also give more insights into underlying regulatory mechanisms behind the pleiotropic effects of rs12373123 in multiple degenerative diseases including AD and Parkinson's disease.",2021,02,Translational psychiatry,11,1,146,,10.1038/s41398-021-01263-4,33637690,#1571,He 2021,"",""
Ethnic and trans-ethnic genome-wide association studies identify new loci influencing Japanese Alzheimer's disease risk.,Shigemizu D.; Mitsumori R.; Akiyama S.; Miyashita A.; Morizono T.; Higaki S.; Asanomi Y.; Hara N.; Tamiya G.; Kinoshita K.; Ikeuchi T.; Niida S.; Ozaki K.,"Alzheimer's disease (AD) has no cure, but early detection and risk prediction could allow earlier intervention. Genetic risk factors may differ between ethnic populations. To discover novel susceptibility loci of AD in the Japanese population, we conducted a genome-wide association study (GWAS) with 3962 AD cases and 4074 controls. Out of 4,852,957 genetic markers that passed stringent quality control filters, 134 in nine loci, including APOE and SORL1, were convincingly associated with AD. Lead SNPs located in seven novel loci were genotyped in an independent Japanese AD case-control cohort. The novel locus FAM47E reached genome-wide significance in a meta-analysis of association results. This is the first report associating the FAM47E locus with AD in the Japanese population. A trans-ethnic meta-analysis combining the results of the Japanese data sets with summary statistics from stage 1 data of the International Genomics of Alzheimer's Project identified an additional novel susceptibility locus in OR2B2. Our data highlight the importance of performing GWAS in non-European populations.",2021,03,Translational psychiatry,11,1,151,,10.1038/s41398-021-01272-3,33654092,#1570,Shigemizu 2021,"",""
Common variants in Alzheimer's disease and risk stratification by polygenic risk scores.,de Rojas I.; Moreno-Grau S.; Tesi N.; Grenier-Boley B.; Andrade V.; Jansen IE.; Pedersen NL.; Stringa N.; Zettergren A.; Hernández I.; Montrreal L.; Antúnez C.; Antonell A.; Tankard RM.; Bis JC.; Sims R.; Bellenguez C.; Quintela I.; González-Perez A.; Calero M.; Franco-Macías E.; Macías J.; Blesa R.; Cervera-Carles L.; Menéndez-González M.; Frank-García A.; Royo JL.; Moreno F.; Huerto Vilas R.; Baquero M.; Diez-Fairen M.; Lage C.; García-Madrona S.; García-González P.; Alarcón-Martín E.; Valero S.; Sotolongo-Grau O.; Ullgren A.; Naj AC.; Lemstra AW.; Benaque A.; Pérez-Cordón A.; Benussi A.; Rábano A.; Padovani A.; Squassina A.; de Mendonça A.; Arias Pastor A.; Kok AAL.; Meggy A.; Pastor AB.; Espinosa A.; Corma-Gómez A.; Martín Montes A.; Sanabria Á.; DeStefano AL.; Schneider A.; Haapasalo A.; Kinhult Ståhlbom A.; Tybjærg-Hansen A.; Hartmann AM.; Spottke A.; Corbatón-Anchuelo A.; Rongve A.; Borroni B.; Arosio B.; Nacmias B.; Nordestgaard BG.; Kunkle BW.; Charbonnier C.; Abdelnour C.; Masullo C.; Martínez Rodríguez C.; Muñoz-Fernandez C.; Dufouil C.; Graff C.; Ferreira CB.; Chillotti C.; Reynolds CA.; Fenoglio C.; Van Broeckhoven C.; Clark C.; Pisanu C.; Satizabal CL.; Holmes C.; Buiza-Rueda D.; Aarsland D.; Rujescu D.; Alcolea D.; Galimberti D.; Wallon D.; Seripa D.; Grünblatt E.; Dardiotis E.; Düzel E.; Scarpini E.; Conti E.; Rubino E.; Gelpi E.; Rodriguez-Rodriguez E.; Duron E.; Boerwinkle E.; Ferri E.; Tagliavini F.; Küçükali F.; Pasquier F.; Sanchez-Garcia F.; Mangialasche F.; Jessen F.; Nicolas G.; Selbæk G.; Ortega G.; Chêne G.; Hadjigeorgiou G.; Rossi G.; Spalletta G.; Giaccone G.; Grande G.; Binetti G.; Papenberg G.; Hampel H.; Bailly H.; Zetterberg H.; Soininen H.; Karlsson IK.; Alvarez I.; Appollonio I.; Giegling I.; Skoog I.; Saltvedt I.; Rainero I.; Rosas Allende I.; Hort J.; Diehl-Schmid J.; Van Dongen J.; Vidal JS.; Lehtisalo J.; Wiltfang J.; Thomassen JQ.; Kornhuber J.; Haines JL.; Vogelgsang J.; Pineda JA.; Fortea J.; Popp J.; Deckert J.; Buerger K.; Morgan K.; Fließbach K.; Sleegers K.; Molina-Porcel L.; Kilander L.; Weinhold L.; Farrer LA.; Wang LS.; Kleineidam L.; Farotti L.; Parnetti L.; Tremolizzo L.; Hausner L.; Benussi L.; Froelich L.; Ikram MA.; Deniz-Naranjo MC.; Tsolaki M.; Rosende-Roca M.; Löwenmark M.; Hulsman M.; Spallazzi M.; Pericak-Vance MA.; Esiri M.; Bernal Sánchez-Arjona M.; Dalmasso MC.; Martínez-Larrad MT.; Arcaro M.; Nöthen MM.; Fernández-Fuertes M.; Dichgans M.; Ingelsson M.; Herrmann MJ.; Scherer M.; Vyhnalek M.; Kosmidis MH.; Yannakoulia M.; Schmid M.; Ewers M.; Heneka MT.; Wagner M.; Scamosci M.; Kivipelto M.; Hiltunen M.; Zulaica M.; Alegret M.; Fornage M.; Roberto N.; van Schoor NM.; Seidu NM.; Banaj N.; Armstrong NJ.; Scarmeas N.; Scherbaum N.; Goldhardt O.; Hanon O.; Peters O.; Skrobot OA.; Quenez O.; Lerch O.; Bossù P.; Caffarra P.; Dionigi Rossi P.; Sakka P.; Hoffmann P.; Holmans PA.; Fischer P.; Riederer P.; Yang Q.; Marshall R.; Kalaria RN.; Mayeux R.; Vandenberghe R.; Cecchetti R.; Ghidoni R.; Frikke-Schmidt R.; Sorbi S.; Hägg S.; Engelborghs S.; Helisalmi S.; Botne Sando S.; Kern S.; Archetti S.; Boschi S.; Fostinelli S.; Gil S.; Mendoza S.; Mead S.; Ciccone S.; Djurovic S.; Heilmann-Heimbach S.; Riedel-Heller S.; Kuulasmaa T.; Del Ser T.; Lebouvier T.; Polak T.; Ngandu T.; Grimmer T.; Bessi V.; Escott-Price V.; Giedraitis V.; Deramecourt V.; Maier W.; Jian X.; Pijnenburg YAL.;  .;  .;  .;  .;  .; Kehoe PG.; Garcia-Ribas G.; Sánchez-Juan P.; Pastor P.; Pérez-Tur J.; Piñol-Ripoll G.; Lopez de Munain A.; García-Alberca JM.; Bullido MJ.; Álvarez V.; Lleó A.; Real LM.; Mir P.; Medina M.; Scheltens P.; Holstege H.; Marquié M.; Sáez ME.; Carracedo Á.; Amouyel P.; Schellenberg GD.; Williams J.; Seshadri S.; van Duijn CM.; Mather KA.; Sánchez-Valle R.; Serrano-Ríos M.; Orellana A.; Tárraga L.; Blennow K.; Huisman M.; Andreassen OA.; Posthuma D.; Clarimón J.; Boada M.; van der Flier WM.; Ramirez A.; Lambert JC.; van der Lee SJ.; Ruiz A.,"Genetic discoveries of Alzheimer's disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer's disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer's disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer's disease.",2021,06,Nature communications,12,1,3417,,10.1038/s41467-021-22491-8,34099642,#1568,deRojas 2021,"",""
Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis.,Kunkle BW.; Schmidt M.; Klein HU.; Naj AC.; Hamilton-Nelson KL.; Larson EB.; Evans DA.; De Jager PL.; Crane PK.; Buxbaum JD.; Ertekin-Taner N.; Barnes LL.; Fallin MD.; Manly JJ.; Go RCP.; Obisesan TO.; Kamboh MI.; Bennett DA.; Hall KS.; Goate AM.; Foroud TM.; Martin ER.; Wang LS.; Byrd GS.; Farrer LA.; Haines JL.; Schellenberg GD.; Mayeux R.; Pericak-Vance MA.; Reitz C.;  .; Graff-Radford NR.; Martinez I.; Ayodele T.; Logue MW.; Cantwell LB.; Jean-Francois M.; Kuzma AB.; Adams LD.; Vance JM.; Cuccaro ML.; Chung J.; Mez J.; Lunetta KL.; Jun GR.; Lopez OL.; Hendrie HC.; Reiman EM.; Kowall NW.; Leverenz JB.; Small SA.; Levey AI.; Golde TE.; Saykin AJ.; Starks TD.; Albert MS.; Hyman BT.; Petersen RC.; Sano M.; Wisniewski T.; Vassar R.; Kaye JA.; Henderson VW.; DeCarli C.; LaFerla FM.; Brewer JB.; Miller BL.; Swerdlow RH.; Van Eldik LJ.; Paulson HL.; Trojanowski JQ.; Chui HC.; Rosenberg RN.; Craft S.; Grabowski TJ.; Asthana S.; Morris JC.; Strittmatter SM.; Kukull WA.,"Compared with non-Hispanic White individuals, African American individuals from the same community are approximately twice as likely to develop Alzheimer disease. Despite this disparity, the largest Alzheimer disease genome-wide association studies to date have been conducted in non-Hispanic White individuals. In the largest association analyses of Alzheimer disease in African American individuals, ABCA7, TREM2, and an intergenic locus at 5q35 were previously implicated. To identify additional risk loci in African American individuals by increasing the sample size and using the African Genome Resource panel. This genome-wide association meta-analysis used case-control and family-based data sets from the Alzheimer Disease Genetics Consortium. There were multiple recruitment sites throughout the United States that included individuals with Alzheimer disease and controls of African American ancestry. Analysis began October 2018 and ended September 2019. Diagnosis of Alzheimer disease. A total of 2784 individuals with Alzheimer disease (1944 female [69.8%]) and 5222 controls (3743 female [71.7%]) were analyzed (mean [SD] age at last evaluation, 74.2 [13.6] years). Associations with 4 novel common loci centered near the intracellular glycoprotein trafficking gene EDEM1 (3p26; P = 8.9 × 10-7), near the immune response gene ALCAM (3q13; P = 9.3 × 10-7), within GPC6 (13q31; P = 4.1 × 10-7), a gene critical for recruitment of glutamatergic receptors to the neuronal membrane, and within VRK3 (19q13.33; P = 3.5 × 10-7), a gene involved in glutamate neurotoxicity, were identified. In addition, several loci associated with rare variants, including a genome-wide significant intergenic locus near IGF1R at 15q26 (P = 1.7 × 10-9) and 6 additional loci with suggestive significance (P ≤ 5 × 10-7) such as API5 at 11p12 (P = 8.8 × 10-8) and RBFOX1 at 16p13 (P = 5.4 × 10-7) were identified. Gene expression data from brain tissue demonstrate association of ALCAM, ARAP1, GPC6, and RBFOX1 with brain β-amyloid load. Of 25 known loci associated with Alzheimer disease in non-Hispanic White individuals, only APOE, ABCA7, TREM2, BIN1, CD2AP, FERMT2, and WWOX were implicated at a nominal significance level or stronger in African American individuals. Pathway analyses strongly support the notion that immunity, lipid processing, and intracellular trafficking pathways underlying Alzheimer disease in African American individuals overlap with those observed in non-Hispanic White individuals. A new pathway emerging from these analyses is the kidney system, suggesting a novel mechanism for Alzheimer disease that needs further exploration. While the major pathways involved in Alzheimer disease etiology in African American individuals are similar to those in non-Hispanic White individuals, the disease-associated loci within these pathways differ.",2021,01,JAMA neurology,78,1,102-113,,10.1001/jamaneurol.2020.3536,33074286,#1575,Kunkle 2021,"",""
"Genome-wide meta-analysis, fine-mapping and integrative prioritization implicate new Alzheimer's disease risk genes.",Schwartzentruber J.; Cooper S.; Liu JZ.; Barrio-Hernandez I.; Bello E.; Kumasaka N.; Young AMH.; Franklin RJM.; Johnson T.; Estrada K.; Gaffney DJ.; Beltrao P.; Bassett A.,"Genome-wide association studies have discovered numerous genomic loci associated with Alzheimer's disease (AD); yet the causal genes and variants are incompletely identified. We performed an updated genome-wide AD meta-analysis, which identified 37 risk loci, including new associations near CCDC6, TSPAN14, NCK2 and SPRED2. Using three SNP-level fine-mapping methods, we identified 21 SNPs with >50% probability each of being causally involved in AD risk and others strongly suggested by functional annotation. We followed this with colocalization analyses across 109 gene expression quantitative trait loci datasets and prioritization of genes by using protein interaction networks and tissue-specific expression. Combining this information into a quantitative score, we found that evidence converged on likely causal genes, including the above four genes, and those at previously discovered AD loci, including BIN1, APH1B, PTK2B, PILRA and CASS4.",2021,03,Nature genetics,53,3,392-402,,10.1038/s41588-020-00776-w,33589840,#1572,Schwartzentruber 2021,"",""
"A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease.",Wightman DP.; Jansen IE.; Savage JE.; Shadrin AA.; Bahrami S.; Holland D.; Rongve A.; Børte S.; Winsvold BS.; Drange OK.; Martinsen AE.; Skogholt AH.; Willer C.; Bråthen G.; Bosnes I.; Nielsen JB.; Fritsche LG.; Thomas LF.; Pedersen LM.; Gabrielsen ME.; Johnsen MB.; Meisingset TW.; Zhou W.; Proitsi P.; Hodges A.; Dobson R.; Velayudhan L.; Heilbron K.; Auton A.;  .; Sealock JM.; Davis LK.; Pedersen NL.; Reynolds CA.; Karlsson IK.; Magnusson S.; Stefansson H.; Thordardottir S.; Jonsson PV.; Snaedal J.; Zettergren A.; Skoog I.; Kern S.; Waern M.; Zetterberg H.; Blennow K.; Stordal E.; Hveem K.; Zwart JA.; Athanasiu L.; Selnes P.; Saltvedt I.; Sando SB.; Ulstein I.; Djurovic S.; Fladby T.; Aarsland D.; Selbæk G.; Ripke S.; Stefansson K.; Andreassen OA.; Posthuma D.,"Late-onset Alzheimer's disease is a prevalent age-related polygenic disease that accounts for 50-70% of dementia cases. Currently, only a fraction of the genetic variants underlying Alzheimer's disease have been identified. Here we show that increased sample sizes allowed identification of seven previously unidentified genetic loci contributing to Alzheimer's disease. This study highlights microglia, immune cells and protein catabolism as relevant to late-onset Alzheimer's disease, while identifying and prioritizing previously unidentified genes of potential interest. We anticipate that these results can be included in larger meta-analyses of Alzheimer's disease to identify further genetic variants that contribute to Alzheimer's pathology.",2021,09,Nature genetics,53,9,1276-1282,,10.1038/s41588-021-00921-z,34493870,#1564,Wightman 2021,"",""
New insights into the genetic etiology of Alzheimer's disease and related dementias.,Bellenguez C.; Küçükali F.; Jansen IE.; Kleineidam L.; Moreno-Grau S.; Amin N.; Naj AC.; Campos-Martin R.; Grenier-Boley B.; Andrade V.; Holmans PA.; Boland A.; Damotte V.; van der Lee SJ.; Costa MR.; Kuulasmaa T.; Yang Q.; de Rojas I.; Bis JC.; Yaqub A.; Prokic I.; Chapuis J.; Ahmad S.; Giedraitis V.; Aarsland D.; Garcia-Gonzalez P.; Abdelnour C.; Alarcón-Martín E.; Alcolea D.; Alegret M.; Alvarez I.; Álvarez V.; Armstrong NJ.; Tsolaki A.; Antúnez C.; Appollonio I.; Arcaro M.; Archetti S.; Pastor AA.; Arosio B.; Athanasiu L.; Bailly H.; Banaj N.; Baquero M.; Barral S.; Beiser A.; Pastor AB.; Below JE.; Benchek P.; Benussi L.; Berr C.; Besse C.; Bessi V.; Binetti G.; Bizarro A.; Blesa R.; Boada M.; Boerwinkle E.; Borroni B.; Boschi S.; Bossù P.; Bråthen G.; Bressler J.; Bresner C.; Brodaty H.; Brookes KJ.; Brusco LI.; Buiza-Rueda D.; Bûrger K.; Burholt V.; Bush WS.; Calero M.; Cantwell LB.; Chene G.; Chung J.; Cuccaro ML.; Carracedo Á.; Cecchetti R.; Cervera-Carles L.; Charbonnier C.; Chen HH.; Chillotti C.; Ciccone S.; Claassen JAHR.; Clark C.; Conti E.; Corma-Gómez A.; Costantini E.; Custodero C.; Daian D.; Dalmasso MC.; Daniele A.; Dardiotis E.; Dartigues JF.; de Deyn PP.; de Paiva Lopes K.; de Witte LD.; Debette S.; Deckert J.; Del Ser T.; Denning N.; DeStefano A.; Dichgans M.; Diehl-Schmid J.; Diez-Fairen M.; Rossi PD.; Djurovic S.; Duron E.; Düzel E.; Dufouil C.; Eiriksdottir G.; Engelborghs S.; Escott-Price V.; Espinosa A.; Ewers M.; Faber KM.; Fabrizio T.; Nielsen SF.; Fardo DW.; Farotti L.; Fenoglio C.; Fernández-Fuertes M.; Ferrari R.; Ferreira CB.; Ferri E.; Fin B.; Fischer P.; Fladby T.; Fließbach K.; Fongang B.; Fornage M.; Fortea J.; Foroud TM.; Fostinelli S.; Fox NC.; Franco-Macías E.; Bullido MJ.; Frank-García A.; Froelich L.; Fulton-Howard B.; Galimberti D.; García-Alberca JM.; García-González P.; Garcia-Madrona S.; Garcia-Ribas G.; Ghidoni R.; Giegling I.; Giorgio G.; Goate AM.; Goldhardt O.; Gomez-Fonseca D.; González-Pérez A.; Graff C.; Grande G.; Green E.; Grimmer T.; Grünblatt E.; Grunin M.; Gudnason V.; Guetta-Baranes T.; Haapasalo A.; Hadjigeorgiou G.; Haines JL.; Hamilton-Nelson KL.; Hampel H.; Hanon O.; Hardy J.; Hartmann AM.; Hausner L.; Harwood J.; Heilmann-Heimbach S.; Helisalmi S.; Heneka MT.; Hernández I.; Herrmann MJ.; Hoffmann P.; Holmes C.; Holstege H.; Vilas RH.; Hulsman M.; Humphrey J.; Biessels GJ.; Jian X.; Johansson C.; Jun GR.; Kastumata Y.; Kauwe J.; Kehoe PG.; Kilander L.; Ståhlbom AK.; Kivipelto M.; Koivisto A.; Kornhuber J.; Kosmidis MH.; Kukull WA.; Kuksa PP.; Kunkle BW.; Kuzma AB.; Lage C.; Laukka EJ.; Launer L.; Lauria A.; Lee CY.; Lehtisalo J.; Lerch O.; Lleó A.; Longstreth W.; Lopez O.; de Munain AL.; Love S.; Löwemark M.; Luckcuck L.; Lunetta KL.; Ma Y.; Macías J.; MacLeod CA.; Maier W.; Mangialasche F.; Spallazzi M.; Marquié M.; Marshall R.; Martin ER.; Montes AM.; Rodríguez CM.; Masullo C.; Mayeux R.; Mead S.; Mecocci P.; Medina M.; Meggy A.; Mehrabian S.; Mendoza S.; Menéndez-González M.; Mir P.; Moebus S.; Mol M.; Molina-Porcel L.; Montrreal L.; Morelli L.; Moreno F.; Morgan K.; Mosley T.; Nöthen MM.; Muchnik C.; Mukherjee S.; Nacmias B.; Ngandu T.; Nicolas G.; Nordestgaard BG.; Olaso R.; Orellana A.; Orsini M.; Ortega G.; Padovani A.; Paolo C.; Papenberg G.; Parnetti L.; Pasquier F.; Pastor P.; Peloso G.; Pérez-Cordón A.; Pérez-Tur J.; Pericard P.; Peters O.; Pijnenburg YAL.; Pineda JA.; Piñol-Ripoll G.; Pisanu C.; Polak T.; Popp J.; Posthuma D.; Priller J.; Puerta R.; Quenez O.; Quintela I.; Thomassen JQ.; Rábano A.; Rainero I.; Rajabli F.; Ramakers I.; Real LM.; Reinders MJT.; Reitz C.; Reyes-Dumeyer D.; Ridge P.; Riedel-Heller S.; Riederer P.; Roberto N.; Rodriguez-Rodriguez E.; Rongve A.; Allende IR.; Rosende-Roca M.; Royo JL.; Rubino E.; Rujescu D.; Sáez ME.; Sakka P.; Saltvedt I.; Sanabria Á.; Sánchez-Arjona MB.; Sanchez-Garcia F.; Juan PS.; Sánchez-Valle R.; Sando SB.; Sarnowski C.; Satizabal CL.; Scamosci M.; Scarmeas N.; Scarpini E.; Scheltens P.; Scherbaum N.; Scherer M.; Schmid M.; Schneider A.; Schott JM.; Selbæk G.; Seripa D.; Serrano M.; Sha J.; Shadrin AA.; Skrobot O.; Slifer S.; Snijders GJL.; Soininen H.; Solfrizzi V.; Solomon A.; Song Y.; Sorbi S.; Sotolongo-Grau O.; Spalletta G.; Spottke A.; Squassina A.; Stordal E.; Tartan JP.; Tárraga L.; Tesí N.; Thalamuthu A.; Thomas T.; Tosto G.; Traykov L.; Tremolizzo L.; Tybjærg-Hansen A.; Uitterlinden A.; Ullgren A.; Ulstein I.; Valero S.; Valladares O.; Broeckhoven CV.; Vance J.; Vardarajan BN.; van der Lugt A.; Dongen JV.; van Rooij J.; van Swieten J.; Vandenberghe R.; Verhey F.; Vidal JS.; Vogelgsang J.; Vyhnalek M.; Wagner M.; Wallon D.; Wang LS.; Wang R.; Weinhold L.; Wiltfang J.; Windle G.; Woods B.; Yannakoulia M.; Zare H.; Zhao Y.; Zhang X.; Zhu C.; Zulaica M.;  .;  .;  .;  .;  .;  .;  .;  .;  .; Farrer LA.; Psaty BM.; Ghanbari M.; Raj T.; Sachdev P.; Mather K.; Jessen F.; Ikram MA.; de Mendonça A.; Hort J.; Tsolaki M.; Pericak-Vance MA.; Amouyel P.; Williams J.; Frikke-Schmidt R.; Clarimon J.; Deleuze JF.; Rossi G.; Seshadri S.; Andreassen OA.; Ingelsson M.; Hiltunen M.; Sleegers K.; Schellenberg GD.; van Duijn CM.; Sims R.; van der Flier WM.; Ruiz A.; Ramirez A.; Lambert JC.,"Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.",2022,04,Nature genetics,54,4,412-436,,10.1038/s41588-022-01024-z,35379992,#1562,Bellenguez 2022,"",""
Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease.,Fernández MV.; Budde J.; Del-Aguila JL.; Ibañez L.; Deming Y.; Harari O.; Norton J.; Morris JC.; Goate AM.;  .;  .; Cruchaga C.,"Gene-based tests to study the combined effect of rare variants on a particular phenotype have been widely developed for case-control studies, but their evolution and adaptation for family-based studies, especially studies of complex incomplete families, has been slower. In this study, we have performed a practical examination of all the latest gene-based methods available for family-based study designs using both simulated and real datasets. We examined the performance of several collapsing, variance-component, and transmission disequilibrium tests across eight different software packages and 22 models utilizing a cohort of 285 families (N = 1,235) with late-onset Alzheimer disease (LOAD). After a thorough examination of each of these tests, we propose a methodological approach to identify, with high confidence, genes associated with the tested phenotype and we provide recommendations to select the best software and model for family-based gene-based analyses. Additionally, in our dataset, we identified PTK2B, a GWAS candidate gene for sporadic AD, along with six novel genes (CHRD, CLCN2, HDLBP, CPAMD8, NLRP9, and MAS1L) as candidate genes for familial LOAD.",2018,,Frontiers in neuroscience,12,,209,,10.3389/fnins.2018.00209,29670507,#1529,Fernández 2018,"",""
"Family-based association analyses of imputed genotypes reveal genome-wide significant association of Alzheimer's disease with OSBPL6, PTPRG, and PDCL3.",Herold C.; Hooli BV.; Mullin K.; Liu T.; Roehr JT.; Mattheisen M.; Parrado AR.; Bertram L.; Lange C.; Tanzi RE.,"The genetic basis of Alzheimer's disease (AD) is complex and heterogeneous. Over 200 highly penetrant pathogenic variants in the genes APP, PSEN1, and PSEN2 cause a subset of early-onset familial AD. On the other hand, susceptibility to late-onset forms of AD (LOAD) is indisputably associated to the ɛ4 allele in the gene APOE, and more recently to variants in more than two-dozen additional genes identified in the large-scale genome-wide association studies (GWAS) and meta-analyses reports. Taken together however, although the heritability in AD is estimated to be as high as 80%, a large proportion of the underlying genetic factors still remain to be elucidated. In this study, we performed a systematic family-based genome-wide association and meta-analysis on close to 15 million imputed variants from three large collections of AD families (~3500 subjects from 1070 families). Using a multivariate phenotype combining affection status and onset age, meta-analysis of the association results revealed three single nucleotide polymorphisms (SNPs) that achieved genome-wide significance for association with AD risk: rs7609954 in the gene PTPRG (P-value=3.98 × 10-8), rs1347297 in the gene OSBPL6 (P-value=4.53 × 10-8), and rs1513625 near PDCL3 (P-value=4.28 × 10-8). In addition, rs72953347 in OSBPL6 (P-value=6.36 × 10-7) and two SNPs in the gene CDKAL1 showed marginally significant association with LOAD (rs10456232, P-value=4.76 × 10-7; rs62400067, P-value=3.54 × 10-7). In summary, family-based GWAS meta-analysis of imputed SNPs revealed novel genomic variants in (or near) PTPRG, OSBPL6, and PDCL3 that influence risk for AD with genome-wide significance.",2016,11,Molecular psychiatry,21,11,1608-1612,,10.1038/mp.2015.218,26830138,#1443,Herold 2016,"",""
"Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans.",Mez J.; Chung J.; Jun G.; Kriegel J.; Bourlas AP.; Sherva R.; Logue MW.; Barnes LL.; Bennett DA.; Buxbaum JD.; Byrd GS.; Crane PK.; Ertekin-Taner N.; Evans D.; Fallin MD.; Foroud T.; Goate A.; Graff-Radford NR.; Hall KS.; Kamboh MI.; Kukull WA.; Larson EB.; Manly JJ.;  .; Haines JL.; Mayeux R.; Pericak-Vance MA.; Schellenberg GD.; Lunetta KL.; Farrer LA.,"African Americans' (AAs) late-onset Alzheimer's disease (LOAD) genetic risk profile is incompletely understood. Including clinical covariates in genetic analyses using informed conditioning might improve study power. We conducted a genome-wide association study (GWAS) in AAs employing informed conditioning in 1825 LOAD cases and 3784 cognitively normal controls. We derived a posterior liability conditioned on age, sex, diabetes status, current smoking status, educational attainment, and affection status, with parameters informed by external prevalence information. We assessed association between the posterior liability and a genome-wide set of single-nucleotide polymorphisms (SNPs), controlling for APOE and ABCA7, identified previously in a LOAD GWAS of AAs. Two SNPs at novel loci, rs112404845 (P = 3.8 × 10-8), upstream of COBL, and rs16961023 (P = 4.6 × 10-8), downstream of SLC10A2, obtained genome-wide significant evidence of association with the posterior liability. An informed conditioning approach can detect LOAD genetic associations in AAs not identified by traditional GWAS.",2017,02,Alzheimer's & dementia : the journal of the Alzheimer's Association,13,2,119-129,,10.1016/j.jalz.2016.09.002,27770636,#1470,Mez 2017,"",""
Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation.,Bis JC.; Jian X.; Kunkle BW.; Chen Y.; Hamilton-Nelson KL.; Bush WS.; Salerno WJ.; Lancour D.; Ma Y.; Renton AE.; Marcora E.; Farrell JJ.; Zhao Y.; Qu L.; Ahmad S.; Amin N.; Amouyel P.; Beecham GW.; Below JE.; Campion D.; Cantwell L.; Charbonnier C.; Chung J.; Crane PK.; Cruchaga C.; Cupples LA.; Dartigues JF.; Debette S.; Deleuze JF.; Fulton L.; Gabriel SB.; Genin E.; Gibbs RA.; Goate A.; Grenier-Boley B.; Gupta N.; Haines JL.; Havulinna AS.; Helisalmi S.; Hiltunen M.; Howrigan DP.; Ikram MA.; Kaprio J.; Konrad J.; Kuzma A.; Lander ES.; Lathrop M.; Lehtimäki T.; Lin H.; Mattila K.; Mayeux R.; Muzny DM.; Nasser W.; Neale B.; Nho K.; Nicolas G.; Patel D.; Pericak-Vance MA.; Perola M.; Psaty BM.; Quenez O.; Rajabli F.; Redon R.; Reitz C.; Remes AM.; Salomaa V.; Sarnowski C.; Schmidt H.; Schmidt M.; Schmidt R.; Soininen H.; Thornton TA.; Tosto G.; Tzourio C.; van der Lee SJ.; van Duijn CM.; Valladares O.; Vardarajan B.; Wang LS.; Wang W.; Wijsman E.; Wilson RK.; Witten D.; Worley KC.; Zhang X.;  .; Bellenguez C.; Lambert JC.; Kurki MI.; Palotie A.; Daly M.; Boerwinkle E.; Lunetta KL.; Destefano AL.; Dupuis J.; Martin ER.; Schellenberg GD.; Seshadri S.; Naj AC.; Fornage M.; Farrer LA.,"The Alzheimer's Disease Sequencing Project (ADSP) undertook whole exome sequencing in 5,740 late-onset Alzheimer disease (AD) cases and 5,096 cognitively normal controls primarily of European ancestry (EA), among whom 218 cases and 177 controls were Caribbean Hispanic (CH). An age-, sex- and APOE based risk score and family history were used to select cases most likely to harbor novel AD risk variants and controls least likely to develop AD by age 85 years. We tested ~1.5 million single nucleotide variants (SNVs) and 50,000 insertion-deletion polymorphisms (indels) for association to AD, using multiple models considering individual variants as well as gene-based tests aggregating rare, predicted functional, and loss of function variants. Sixteen single variants and 19 genes that met criteria for significant or suggestive associations after multiple-testing correction were evaluated for replication in four independent samples; three with whole exome sequencing (2,778 cases, 7,262 controls) and one with genome-wide genotyping imputed to the Haplotype Reference Consortium panel (9,343 cases, 11,527 controls). The top findings in the discovery sample were also followed-up in the ADSP whole-genome sequenced family-based dataset (197 members of 42 EA families and 501 members of 157 CH families). We identified novel and predicted functional genetic variants in genes previously associated with AD. We also detected associations in three novel genes: IGHG3 (p = 9.8 × 10-7), an immunoglobulin gene whose antibodies interact with β-amyloid, a long non-coding RNA AC099552.4 (p = 1.2 × 10-7), and a zinc-finger protein ZNF655 (gene-based p = 5.0 × 10-6). The latter two suggest an important role for transcriptional regulation in AD pathogenesis.",2020,Aug,Molecular psychiatry,25,8,1859-1875,,10.1038/s41380-018-0112-7,30108311,#1464,Bis 2020,"",""
Correction: Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation.,Bis JC.; Jian X.; Kunkle BW.; Chen Y.; Hamilton-Nelson KL.; Bush WS.; Salerno WJ.; Lancour D.; Ma Y.; Renton AE.; Marcora E.; Farrell JJ.; Zhao Y.; Qu L.; Ahmad S.; Amin N.; Amouyel P.; Beecham GW.; Below JE.; Campion D.; Cantwell L.; Charbonnier C.; Chung J.; Crane PK.; Cruchaga C.; Cupples LA.; Dartigues JF.; Debette S.; Deleuze JF.; Fulton L.; Gabriel SB.; Genin E.; Gibbs RA.; Goate A.; Grenier-Boley B.; Gupta N.; Haines JL.; Havulinna AS.; Helisalmi S.; Hiltunen M.; Howrigan DP.; Ikram MA.; Kaprio J.; Konrad J.; Kuzma A.; Lander ES.; Lathrop M.; Lehtimäki T.; Lin H.; Mattila K.; Mayeux R.; Muzny DM.; Nasser W.; Neale B.; Nho K.; Nicolas G.; Patel D.; Pericak-Vance MA.; Perola M.; Psaty BM.; Quenez O.; Rajabli F.; Redon R.; Reitz C.; Remes AM.; Salomaa V.; Sarnowski C.; Schmidt H.; Schmidt M.; Schmidt R.; Soininen H.; Thornton TA.; Tosto G.; Tzourio C.; van der Lee SJ.; van Duijn CM.; Valladares O.; Vardarajan B.; Wang LS.; Wang W.; Wijsman E.; Wilson RK.; Witten D.; Worley KC.; Zhang X.;  .; Bellenguez C.; Lambert JC.; Kurki MI.; Palotie A.; Daly M.; Boerwinkle E.; Lunetta KL.; Destefano AL.; Dupuis J.; Martin ER.; Schellenberg GD.; Seshadri S.; Naj AC.; Fornage M.; Farrer LA.,A correction to this paper has been published and can be accessed via a link at the top of the paper.,2020,Aug,Molecular psychiatry,25,8,1901-1903,,10.1038/s41380-019-0529-7,31636380,#1464,Bis 2020,"",""
Strong impact of natural-selection-free heterogeneity in genetics of age-related phenotypes.,Kulminski AM.; Huang J.; Loika Y.; Arbeev KG.; Bagley O.; Yashkin A.; Duan M.; Culminskaya I.,"A conceptual difficulty in genetics of age-related phenotypes that make individuals vulnerable to disease in post-reproductive life is genetic heterogeneity attributed to an undefined role of evolution in establishing their molecular mechanisms. Here, we performed univariate and pleiotropic genome-wide meta-analyses of 20 age-related phenotypes leveraging longitudinal information in a sample of 33,431 individuals and dealing with the natural-selection-free genetic heterogeneity. We identified 142 non-proxy single nucleotide polymorphisms (SNPs) with phenotype-specific (18 SNPs) and pleiotropic (124 SNPs) associations at genome-wide level. Univariate meta-analysis identified two novel (11.1%) and replicated 16 SNPs whereas pleiotropic meta-analysis identified 115 novel (92.7%) and nine replicated SNPs. Pleiotropic associations for most novel (93.9%) and all replicated SNPs were strongly impacted by the natural-selection-free genetic heterogeneity in its unconventional form of antagonistic heterogeneity, implying antagonistic directions of genetic effects for directly correlated phenotypes. Our results show that the common genome-wide approach is well adapted to handle homogeneous univariate associations within Mendelian framework whereas most associations with age-related phenotypes are more complex and well beyond that framework. Dissecting the natural-selection-free genetic heterogeneity is critical for gaining insights into genetics of age-related phenotypes and has substantial and unexplored yet potential for improving efficiency of genome-wide analysis.",2018,03,Aging,10,3,492-514,,10.18632/aging.101407,29615537,#1449,Kulminski 2018,"",""
Association of Variants in PINX1 and TREM2 With Late-Onset Alzheimer Disease.,Tosto G.; Vardarajan B.; Sariya S.; Brickman AM.; Andrews H.; Manly JJ.; Schupf N.; Reyes-Dumeyer D.; Lantigua R.; Bennett DA.; De Jager PL.; Mayeux R.,"Genetic causes of late-onset Alzheimer disease (LOAD) are not completely explained by known genetic loci. Whole-exome and whole-genome sequencing can improve the understanding of the causes of LOAD and provide initial steps required to identify potential therapeutic targets. To identify the genetic loci for LOAD across different ethnic groups. This multicenter cohort study was designed to analyze whole-exome sequencing data from a multiethnic cohort using a transethnic gene-kernel association test meta-analysis, adjusted for sex, age, and principal components, to identify genetic variants associated with LOAD. A meta-analysis was conducted on the results of 2 independent studies of whole-exome and whole-genome sequence data from individuals of European ancestry. This group of European American, African American, and Caribbean Hispanic individuals participating in an urban population-based study were the discovery cohort; the additional cohorts included affected individuals and control participants from 2 publicly available data sets. Replication was achieved using independent data sets from Caribbean Hispanic families with multiple family members affected by LOAD and the International Genetics of Alzheimer Project. Late-onset Alzheimer disease. The discovery cohort included 3595 affected individuals, while the additional cohorts included 5931 individuals with LOAD and 5504 control participants. Of 3916 individuals in the discovery cohort, we included 3595 individuals (1397 with LOAD and 2198 cognitively healthy controls; 2451 [68.2%] women; mean [SD] age, 80.3 [6.83] years). Another 321 individuals (8.2%) were excluded because of non-LOAD diagnosis, age younger than 60 years, missing covariates, duplicate data, or genetic outlier status. Gene-based tests that compared affected individuals (n = 7328) and control participants (n = 7702) and included only rare and uncommon variants annotated as having moderate-high functional effect supported PINX1 (8p23.1) as a locus with gene-wide significance (P = 2.81 × 10-6) after meta-analysis across the 3 studies. The PINX1 finding was replicated using data from the family-based study and the International Genetics of Alzheimer Project. Full meta-analysis of discovery and replication cohorts reached a P value of 6.16 × 10-7 for PINX1 (in 7620 affected individuals vs 7768 control participants). We also identified TREM2 in an annotation model that prioritized highly deleterious variants with a combined annotation dependent depletion greater than 20 (P= 1.0 × 10-7). This gene-based, transethnic approach identified PINX1, a gene involved in telomere integrity, and TREM2, a gene with a product of an immune receptor found in microglia, as associated with LOAD. Both genes have well-established roles in aging and neurodegeneration.",2019,May,JAMA neurology,,,,,10.1001/jamaneurol.2019.1066,31058951,#1547,Tosto 2019,"",""
"Alzheimer Disease Pathology-Associated Polymorphism in a Complex Variable Number of Tandem Repeat Region Within the MUC6 Gene, Near the AP2A2 Gene.",Katsumata Y.; Fardo DW.; Bachstetter AD.; Artiushin SC.; Wang WX.; Wei A.; Brzezinski LJ.; Nelson BG.; Huang Q.; Abner EL.; Anderson S.; Patel I.; Shaw BC.; Price DA.; Niedowicz DM.; Wilcock DW.; Jicha GA.; Neltner JH.; Van Eldik LJ.; Estus S.; Nelson PT.,"We found evidence of late-onset Alzheimer disease (LOAD)-associated genetic polymorphism within an exon of Mucin 6 (MUC6) and immediately downstream from another gene: Adaptor Related Protein Complex 2 Subunit Alpha 2 (AP2A2). PCR analyses on genomic DNA samples confirmed that the size of the MUC6 variable number tandem repeat (VNTR) region was highly polymorphic. In a cohort of autopsied subjects with quantitative digital pathology data (n = 119), the size of the polymorphic region was associated with the severity of pTau pathology in neocortex. In a separate replication cohort of autopsied subjects (n = 173), more pTau pathology was again observed in subjects with longer VNTR regions (p = 0.031). Unlike MUC6, AP2A2 is highly expressed in human brain. AP2A2 expression was lower in a subset analysis of brain samples from persons with longer versus shorter VNTR regions (p = 0.014 normalizing with AP2B1 expression). Double-label immunofluorescence studies showed that AP2A2 protein often colocalized with neurofibrillary tangles in LOAD but was not colocalized with pTau proteinopathy in progressive supranuclear palsy, or with TDP-43 proteinopathy. In summary, polymorphism in a repeat-rich region near AP2A2 was associated with neocortical pTau proteinopathy (because of the unique repeats, prior genome-wide association studies were probably unable to detect this association), and AP2A2 was often colocalized with neurofibrillary tangles in LOAD.",2020,01,Journal of neuropathology and experimental neurology,79,1,3-21,,10.1093/jnen/nlz116,31748784,#1551,Katsumata 2020,"",""
CDK5RAP2 gene and tau pathophysiology in late-onset sporadic Alzheimer's disease.,Miron J.; Picard C.; Nilsson N.; Frappier J.; Dea D.; Théroux L.;  .;  .; Poirier J.,"Because currently known Alzheimer's disease (AD) single-nucleotide polymorphisms only account for a small fraction of the genetic variance in this disease, there is a need to identify new variants associated with AD. Our team performed a genome-wide association study in the Quebec Founder Population isolate to identify novel protective or risk genetic factors for late-onset sporadic AD and examined the impact of these variants on gene expression and AD pathology. The rs10984186 variant is associated with an increased risk of developing AD and with a higher CDK5RAP2 mRNA prevalence in the hippocampus. On the other hand, the rs4837766 variant, which is among the best cis-expression quantitative trait loci in the CDK5RAP2 gene, is associated with lower mild cognitive impairment/AD risk and conversion rate. The rs10984186 risk and rs4837766 protective polymorphic variants of the CDK5RAP2 gene might act as potent genetic modifiers for AD risk and/or conversion by modulating the expression of this gene.",2018,06,Alzheimer's & dementia : the journal of the Alzheimer's Association,14,6,787-796,,10.1016/j.jalz.2017.12.004,29360470,#1472,Miron 2018,"",""
F-box/LRR-repeat protein 7 is genetically associated with Alzheimer's disease.,Tosto G.; Fu H.; Vardarajan BN.; Lee JH.; Cheng R.; Reyes-Dumeyer D.; Lantigua R.; Medrano M.; Jimenez-Velazquez IZ.; Elkind MS.; Wright CB.; Sacco RL.; Pericak-Vance M.; Farrer L.; Rogaeva E.; St George-Hyslop P.; Reitz C.; Mayeux R.,"In the context of late-onset Alzheimer's disease (LOAD) over 20 genes have been identified but, aside APOE, all show small effect sizes, leaving a large part of the genetic component unexplained. Admixed populations, such as Caribbean Hispanics, can provide a valuable contribution because of their unique genetic profile and higher incidence of the disease. We aimed to identify novel loci associated with LOAD. About 4514 unrelated Caribbean Hispanics (2451 cases and 2063 controls) were selected for genome-wide association analysis. Significant loci were further tested in the expanded cohort that also included related family members (n = 5300). Two AD-like transgenic mice models (J20 and rTg4510) were used to study gene expression. Independent data sets of non-Hispanic Whites and African Americans were used to further validate findings, along with publicly available brain expression data sets. A novel locus, rs75002042 in FBXL7 (5p15.1), was found genome-wide significant in the case-control cohort (odd ratio [OR] = 0.61, P = 6.19E-09) and confirmed in the related members cohorts (OR = 0.63, P = 4.7E-08). Fbxl7 protein was overexpressed in both AD-like transgenic mice compared to wild-type littermates. Publicly available microarray studies also showed significant overexpression of Fbxl7 in LOAD brains compared to nondemented controls. single-nucleotide polymorphism (SNP) rs75002042 was in complete linkage disequilibrium with other variants in two independent non-Hispanic White and African American data sets (0.0005 < P < 0.02) used for replication. FBXL7, encodes a subcellular protein involved in phosphorylation-dependent ubiquitination processes and displays proapoptotic activity. F-box proteins also modulate inflammation and innate immunity, which may be important in LOAD pathogenesis. Further investigations are needed to validate and understand its role in this and other populations.",2015,Aug,Annals of clinical and translational neurology,2,8,810-20,,10.1002/acn3.223,26339675,#1439,Tosto 2015,"",""
A novel Alzheimer disease locus located near the gene encoding tau protein.,Jun G.; Ibrahim-Verbaas CA.; Vronskaya M.; Lambert JC.; Chung J.; Naj AC.; Kunkle BW.; Wang LS.; Bis JC.; Bellenguez C.; Harold D.; Lunetta KL.; Destefano AL.; Grenier-Boley B.; Sims R.; Beecham GW.; Smith AV.; Chouraki V.; Hamilton-Nelson KL.; Ikram MA.; Fievet N.; Denning N.; Martin ER.; Schmidt H.; Kamatani Y.; Dunstan ML.; Valladares O.; Laza AR.; Zelenika D.; Ramirez A.; Foroud TM.; Choi SH.; Boland A.; Becker T.; Kukull WA.; van der Lee SJ.; Pasquier F.; Cruchaga C.; Beekly D.; Fitzpatrick AL.; Hanon O.; Gill M.; Barber R.; Gudnason V.; Campion D.; Love S.; Bennett DA.; Amin N.; Berr C.; Tsolaki M.; Buxbaum JD.; Lopez OL.; Deramecourt V.; Fox NC.; Cantwell LB.; Tárraga L.; Dufouil C.; Hardy J.; Crane PK.; Eiriksdottir G.; Hannequin D.; Clarke R.; Evans D.; Mosley TH.; Letenneur L.; Brayne C.; Maier W.; De Jager P.; Emilsson V.; Dartigues JF.; Hampel H.; Kamboh MI.; de Bruijn RF.; Tzourio C.; Pastor P.; Larson EB.; Rotter JI.; O'Donovan MC.; Montine TJ.; Nalls MA.; Mead S.; Reiman EM.; Jonsson PV.; Holmes C.; St George-Hyslop PH.; Boada M.; Passmore P.; Wendland JR.; Schmidt R.; Morgan K.; Winslow AR.; Powell JF.; Carasquillo M.; Younkin SG.; Jakobsdóttir J.; Kauwe JS.; Wilhelmsen KC.; Rujescu D.; Nöthen MM.; Hofman A.; Jones L.;  .; Haines JL.; Psaty BM.; Van Broeckhoven C.; Holmans P.; Launer LJ.; Mayeux R.; Lathrop M.; Goate AM.; Escott-Price V.; Seshadri S.; Pericak-Vance MA.; Amouyel P.; Williams J.; van Duijn CM.; Schellenberg GD.; Farrer LA.,"APOE ɛ4, the most significant genetic risk factor for Alzheimer disease (AD), may mask effects of other loci. We re-analyzed genome-wide association study (GWAS) data from the International Genomics of Alzheimer's Project (IGAP) Consortium in APOE ɛ4+ (10 352 cases and 9207 controls) and APOE ɛ4- (7184 cases and 26 968 controls) subgroups as well as in the total sample testing for interaction between a single-nucleotide polymorphism (SNP) and APOE ɛ4 status. Suggestive associations (P<1 × 10(-4)) in stage 1 were evaluated in an independent sample (stage 2) containing 4203 subjects (APOE ɛ4+: 1250 cases and 536 controls; APOE ɛ4-: 718 cases and 1699 controls). Among APOE ɛ4- subjects, novel genome-wide significant (GWS) association was observed with 17 SNPs (all between KANSL1 and LRRC37A on chromosome 17 near MAPT) in a meta-analysis of the stage 1 and stage 2 data sets (best SNP, rs2732703, P=5·8 × 10(-9)). Conditional analysis revealed that rs2732703 accounted for association signals in the entire 100-kilobase region that includes MAPT. Except for previously identified AD loci showing stronger association in APOE ɛ4+ subjects (CR1 and CLU) or APOE ɛ4- subjects (MS4A6A/MS4A4A/MS4A6E), no other SNPs were significantly associated with AD in a specific APOE genotype subgroup. In addition, the finding in the stage 1 sample that AD risk is significantly influenced by the interaction of APOE with rs1595014 in TMEM106B (P=1·6 × 10(-7)) is noteworthy, because TMEM106B variants have previously been associated with risk of frontotemporal dementia. Expression quantitative trait locus analysis revealed that rs113986870, one of the GWS SNPs near rs2732703, is significantly associated with four KANSL1 probes that target transcription of the first translated exon and an untranslated exon in hippocampus (P ⩽ 1.3 × 10(-8)), frontal cortex (P ⩽ 1.3 × 10(-9)) and temporal cortex (P⩽1.2 × 10(-11)). Rs113986870 is also strongly associated with a MAPT probe that targets transcription of alternatively spliced exon 3 in frontal cortex (P=9.2 × 10(-6)) and temporal cortex (P=2.6 × 10(-6)). Our APOE-stratified GWAS is the first to show GWS association for AD with SNPs in the chromosome 17q21.31 region. Replication of this finding in independent samples is needed to verify that SNPs in this region have significantly stronger effects on AD risk in persons lacking APOE ɛ4 compared with persons carrying this allele, and if this is found to hold, further examination of this region and studies aimed at deciphering the mechanism(s) are warranted.",2016,Jan,Molecular psychiatry,21,1,108-17,,10.1038/mp.2015.23,25778476,#1437,Jun 2016,"",""
A rare missense variant of CASP7 is associated with familial late-onset Alzheimer's disease.,Zhang X.; Zhu C.; Beecham G.; Vardarajan BN.; Ma Y.; Lancour D.; Farrell JJ.; Chung J.;  .; Mayeux R.; Haines JL.; Schellenberg GD.; Pericak-Vance MA.; Lunetta KL.; Farrer LA.,"The genetic architecture of Alzheimer's disease (AD) is only partially understood. We conducted an association study for AD using whole sequence data from 507 genetically enriched AD cases (i.e., cases having close relatives affected by AD) and 4917 cognitively healthy controls of European ancestry (EA) and 172 enriched cases and 179 controls of Caribbean Hispanic ancestry. Confirmation of top findings from stage 1 was sought in two family-based genome-wide association study data sets and in a whole genome-sequencing data set comprising members from 42 EA and 115 Caribbean Hispanic families. We identified associations in EAs with variants in 12 novel loci. The most robust finding is a rare CASP7 missense variant (rs116437863; P = 2.44 × 10-10) which improved when combined with results from stage 2 data sets (P = 1.92 × 10-10). Our study demonstrated that an enriched case design can strengthen genetic signals, thus allowing detection of associations that would otherwise be missed in a traditional case-control study.",2019,03,Alzheimer's & dementia : the journal of the Alzheimer's Association,15,3,441-452,,10.1016/j.jalz.2018.10.005,30503768,#1465,Zhang 2019,"",""
Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project.,Moreno-Grau S.; de Rojas I.; Hernández I.; Quintela I.; Montrreal L.; Alegret M.; Hernández-Olasagarre B.; Madrid L.; González-Perez A.; Maroñas O.; Rosende-Roca M.; Mauleón A.; Vargas L.; Lafuente A.; Abdelnour C.; Rodríguez-Gómez O.; Gil S.; Santos-Santos MÁ.; Espinosa A.; Ortega G.; Sanabria Á.; Pérez-Cordón A.; Cañabate P.; Moreno M.; Preckler S.; Ruiz S.; Aguilera N.; Pineda JA.; Macías J.; Alarcón-Martín E.; Sotolongo-Grau O.;  .;  .;  .; Marquié M.; Monté-Rubio G.; Valero S.; Benaque A.; Clarimón J.; Bullido MJ.; García-Ribas G.; Pástor P.; Sánchez-Juan P.; Álvarez V.; Piñol-Ripoll G.; García-Alberca JM.; Royo JL.; Franco E.; Mir P.; Calero M.; Medina M.; Rábano A.; Ávila J.; Antúnez C.; Real LM.; Orellana A.; Carracedo Á.; Sáez ME.; Tárraga L.; Boada M.; Ruiz A.,"Large variability among Alzheimer's disease (AD) cases might impact genetic discoveries and complicate dissection of underlying biological pathways. Genome Research at Fundacio ACE (GR@ACE) is a genome-wide study of dementia and its clinical endophenotypes, defined based on AD's clinical certainty and vascular burden. We assessed the impact of known AD loci across endophenotypes to generate loci categories. We incorporated gene coexpression data and conducted pathway analysis per category. Finally, to evaluate the effect of heterogeneity in genetic studies, GR@ACE series were meta-analyzed with additional genome-wide association study data sets. We classified known AD loci into three categories, which might reflect the disease clinical heterogeneity. Vascular processes were only detected as a causal mechanism in probable AD. The meta-analysis strategy revealed the ANKRD31-rs4704171 and NDUFAF6-rs10098778 and confirmed SCIMP-rs7225151 and CD33-rs3865444. The regulation of vasculature is a prominent causal component of probable AD. GR@ACE meta-analysis revealed novel AD genetic signals, strongly driven by the presence of clinical heterogeneity in the AD series.",2019,10,Alzheimer's & dementia : the journal of the Alzheimer's Association,15,10,1333-1347,,10.1016/j.jalz.2019.06.4950,31473137,#1459,Moreno-Grau 2019,"",""
Transethnic genome-wide scan identifies novel Alzheimer's disease loci.,Jun GR.; Chung J.; Mez J.; Barber R.; Beecham GW.; Bennett DA.; Buxbaum JD.; Byrd GS.; Carrasquillo MM.; Crane PK.; Cruchaga C.; De Jager P.; Ertekin-Taner N.; Evans D.; Fallin MD.; Foroud TM.; Friedland RP.; Goate AM.; Graff-Radford NR.; Hendrie H.; Hall KS.; Hamilton-Nelson KL.; Inzelberg R.; Kamboh MI.; Kauwe JSK.; Kukull WA.; Kunkle BW.; Kuwano R.; Larson EB.; Logue MW.; Manly JJ.; Martin ER.; Montine TJ.; Mukherjee S.; Naj A.; Reiman EM.; Reitz C.; Sherva R.; St George-Hyslop PH.; Thornton T.; Younkin SG.; Vardarajan BN.; Wang LS.; Wendlund JR.; Winslow AR.;  .; Haines J.; Mayeux R.; Pericak-Vance MA.; Schellenberg G.; Lunetta KL.; Farrer LA.,"Genetic loci for Alzheimer's disease (AD) have been identified in whites of European ancestry, but the genetic architecture of AD among other populations is less understood. We conducted a transethnic genome-wide association study (GWAS) for late-onset AD in Stage 1 sample including whites of European Ancestry, African-Americans, Japanese, and Israeli-Arabs assembled by the Alzheimer's Disease Genetics Consortium. Suggestive results from Stage 1 from novel loci were followed up using summarized results in the International Genomics Alzheimer's Project GWAS dataset. Genome-wide significant (GWS) associations in single-nucleotide polymorphism (SNP)-based tests (P < 5 × 10-8) were identified for SNPs in PFDN1/HBEGF, USP6NL/ECHDC3, and BZRAP1-AS1 and for the interaction of the (apolipoprotein E) APOE ε4 allele with NFIC SNP. We also obtained GWS evidence (P < 2.7 × 10-6) for gene-based association in the total sample with a novel locus, TPBG (P = 1.8 × 10-6). Our findings highlight the value of transethnic studies for identifying novel AD susceptibility loci.",2017,Jul,Alzheimer's & dementia : the journal of the Alzheimer's Association,13,7,727-738,,10.1016/j.jalz.2016.12.012,28183528,#1444,Jun 2017,"",""
"Whole-exome sequencing in 20,197 persons for rare variants in Alzheimer's disease.",Raghavan NS.; Brickman AM.; Andrews H.; Manly JJ.; Schupf N.; Lantigua R.; Wolock CJ.; Kamalakaran S.; Petrovski S.; Tosto G.; Vardarajan BN.; Goldstein DB.; Mayeux R.;  .,"The genetic bases of Alzheimer's disease remain uncertain. An international effort to fully articulate genetic risks and protective factors is underway with the hope of identifying potential therapeutic targets and preventive strategies. The goal here was to identify and characterize the frequency and impact of rare and ultra-rare variants in Alzheimer's disease, using whole-exome sequencing in 20,197 individuals. We used a gene-based collapsing analysis of loss-of-function ultra-rare variants in a case-control study design with data from the Washington Heights-Inwood Columbia Aging Project, the Alzheimer's Disease Sequencing Project and unrelated individuals from the Institute of Genomic Medicine at Columbia University. We identified 19 cases carrying extremely rare SORL1 loss-of-function variants among a collection of 6,965 cases and a single loss-of-function variant among 13,252 controls (P = 2.17 × 10-8; OR: 36.2 [95% CI: 5.8-1493.0]). Age-at-onset was 7 years earlier for patients with SORL1 qualifying variant compared with noncarriers. No other gene attained a study-wide level of statistical significance, but multiple top-ranked genes, including GRID2IP,WDR76 and GRN, were among candidates for follow-up studies. This study implicates ultra-rare, loss-of-function variants in SORL1 as a significant genetic risk factor for Alzheimer's disease and provides a comprehensive dataset comparing the burden of rare variation in nearly all human genes in Alzheimer's disease cases and controls. This is the first investigation to establish a genome-wide statistically significant association between multiple extremely rare loss-of-function variants in SORL1 and Alzheimer's disease in a large whole-exome study of unrelated cases and controls.",2018,Jul,Annals of clinical and translational neurology,5,7,832-842,,10.1002/acn3.582,30009200,#1463,Raghavan 2018,"",""
Hidden heterogeneity in Alzheimer's disease: Insights from genetic association studies and other analyses.,Yashin AI.; Fang F.; Kovtun M.; Wu D.; Duan M.; Arbeev K.; Akushevich I.; Kulminski A.; Culminskaya I.; Zhbannikov I.; Yashkin A.; Stallard E.; Ukraintseva S.,"Despite evident success in clarifying many important features of Alzheimer's disease (AD) the efficient methods of its prevention and treatment are not yet available. The reasons are likely to be the fact that AD is a multifactorial and heterogeneous health disorder with multiple alternative pathways of disease development and progression. The availability of genetic data on individuals participated in longitudinal studies of aging health and longevity, as well as on participants of cross-sectional case-control studies allow for investigating genetic and non-genetic connections with AD and to link the results of these analyses with research findings obtained in clinical, experimental, and molecular biological studies of this health disorder. The objective of this paper is to perform GWAS of AD in several study populations and investigate possible roles of detected genetic factors in developing AD hallmarks and in other health disorders. The data collected in the Framingham Heart Study (FHS), Cardiovascular Health Study (CHS), Health and Retirement Study (HRS) and Late Onset Alzheimer's Disease Family Study (LOADFS) were used in these analyses. The logistic regression and Cox's regression were used as statistical models in GWAS. The results of analyses confirmed strong associations of genetic variants from well-known genes APOE, TOMM40, PVRL2 (NECTIN2), and APOC1 with AD. Possible roles of these genes in pathological mechanisms resulting in development of hallmarks of AD are described. Many genes whose connection with AD was detected in other studies showed nominally significant associations with this health disorder in our study. The evidence on genetic connections between AD and vulnerability to infection, as well as between AD and other health disorders, such as cancer and type 2 diabetes, were investigated. The progress in uncovering hidden heterogeneity in AD would be substantially facilitated if common mechanisms involved in development of AD, its hallmarks, and AD related chronic conditions were investigated in their mutual connection.",2018,07,Experimental gerontology,107,,148-160,,10.1016/j.exger.2017.10.020,29107063,#1447,Yashin 2018,"",""
A genome-wide association study of late-onset Alzheimer's disease in a Japanese population.,Hirano A.; Ohara T.; Takahashi A.; Aoki M.; Fuyuno Y.; Ashikawa K.; Morihara T.; Takeda M.; Kamino K.; Oshima E.; Okahisa Y.; Shibata N.; Arai H.; Akatsu H.; Ikeda M.; Iwata N.; Ninomiya T.; Monji A.; Kitazono T.; Kiyohara Y.; Kubo M.; Kanba S.,"Although a number of genome-wide association studies (GWASs) of late-onset Alzheimer's disease (LOAD) have been carried out, there have been little GWAS data on East Asian populations. To discover the novel susceptibility loci of LOAD, we carried out a GWAS using 816 LOAD cases and 7992 controls with a replication analysis using an independent panel of 1011 LOAD cases and 7212 controls in a Japanese population. In addition, we carried out a stratified analysis by APOE-ε4 status to eliminate the established effect of APOE region. Our data indicated that 18p11.32 (rs1992269, P = 9.77 × 10(-7)), CNTNAP2 (rs802571, P = 1.26 × 10(-6)), and 12q24.23 (rs11613092, P = 6.85 × 10(-6)) were suggestive loci for susceptibility to LOAD. We identified three suggestive loci for susceptibility to LOAD in a Japanese population. Among these, rs802571, located at intron 1 of CNTNAP2, was considered to be a plausible candidate locus from a functional perspective.",2015,Aug,Psychiatric genetics,25,4,139-46,,10.1097/YPG.0000000000000090,26049409,#1438,Hirano 2015,"",""
"Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.",Sims R.; van der Lee SJ.; Naj AC.; Bellenguez C.; Badarinarayan N.; Jakobsdottir J.; Kunkle BW.; Boland A.; Raybould R.; Bis JC.; Martin ER.; Grenier-Boley B.; Heilmann-Heimbach S.; Chouraki V.; Kuzma AB.; Sleegers K.; Vronskaya M.; Ruiz A.; Graham RR.; Olaso R.; Hoffmann P.; Grove ML.; Vardarajan BN.; Hiltunen M.; Nöthen MM.; White CC.; Hamilton-Nelson KL.; Epelbaum J.; Maier W.; Choi SH.; Beecham GW.; Dulary C.; Herms S.; Smith AV.; Funk CC.; Derbois C.; Forstner AJ.; Ahmad S.; Li H.; Bacq D.; Harold D.; Satizabal CL.; Valladares O.; Squassina A.; Thomas R.; Brody JA.; Qu L.; Sánchez-Juan P.; Morgan T.; Wolters FJ.; Zhao Y.; Garcia FS.; Denning N.; Fornage M.; Malamon J.; Naranjo MCD.; Majounie E.; Mosley TH.; Dombroski B.; Wallon D.; Lupton MK.; Dupuis J.; Whitehead P.; Fratiglioni L.; Medway C.; Jian X.; Mukherjee S.; Keller L.; Brown K.; Lin H.; Cantwell LB.; Panza F.; McGuinness B.; Moreno-Grau S.; Burgess JD.; Solfrizzi V.; Proitsi P.; Adams HH.; Allen M.; Seripa D.; Pastor P.; Cupples LA.; Price ND.; Hannequin D.; Frank-García A.; Levy D.; Chakrabarty P.; Caffarra P.; Giegling I.; Beiser AS.; Giedraitis V.; Hampel H.; Garcia ME.; Wang X.; Lannfelt L.; Mecocci P.; Eiriksdottir G.; Crane PK.; Pasquier F.; Boccardi V.; Henández I.; Barber RC.; Scherer M.; Tarraga L.; Adams PM.; Leber M.; Chen Y.; Albert MS.; Riedel-Heller S.; Emilsson V.; Beekly D.; Braae A.; Schmidt R.; Blacker D.; Masullo C.; Schmidt H.; Doody RS.; Spalletta G.; Longstreth WT.; Fairchild TJ.; Bossù P.; Lopez OL.; Frosch MP.; Sacchinelli E.; Ghetti B.; Yang Q.; Huebinger RM.; Jessen F.; Li S.; Kamboh MI.; Morris J.; Sotolongo-Grau O.; Katz MJ.; Corcoran C.; Dunstan M.; Braddel A.; Thomas C.; Meggy A.; Marshall R.; Gerrish A.; Chapman J.; Aguilar M.; Taylor S.; Hill M.; Fairén MD.; Hodges A.; Vellas B.; Soininen H.; Kloszewska I.; Daniilidou M.; Uphill J.; Patel Y.; Hughes JT.; Lord J.; Turton J.; Hartmann AM.; Cecchetti R.; Fenoglio C.; Serpente M.; Arcaro M.; Caltagirone C.; Orfei MD.; Ciaramella A.; Pichler S.; Mayhaus M.; Gu W.; Lleó A.; Fortea J.; Blesa R.; Barber IS.; Brookes K.; Cupidi C.; Maletta RG.; Carrell D.; Sorbi S.; Moebus S.; Urbano M.; Pilotto A.; Kornhuber J.; Bosco P.; Todd S.; Craig D.; Johnston J.; Gill M.; Lawlor B.; Lynch A.; Fox NC.; Hardy J.;  .; Albin RL.; Apostolova LG.; Arnold SE.; Asthana S.; Atwood CS.; Baldwin CT.; Barnes LL.; Barral S.; Beach TG.; Becker JT.; Bigio EH.; Bird TD.; Boeve BF.; Bowen JD.; Boxer A.; Burke JR.; Burns JM.; Buxbaum JD.; Cairns NJ.; Cao C.; Carlson CS.; Carlsson CM.; Carney RM.; Carrasquillo MM.; Carroll SL.; Diaz CC.; Chui HC.; Clark DG.; Cribbs DH.; Crocco EA.; DeCarli C.; Dick M.; Duara R.; Evans DA.; Faber KM.; Fallon KB.; Fardo DW.; Farlow MR.; Ferris S.; Foroud TM.; Galasko DR.; Gearing M.; Geschwind DH.; Gilbert JR.; Graff-Radford NR.; Green RC.; Growdon JH.; Hamilton RL.; Harrell LE.; Honig LS.; Huentelman MJ.; Hulette CM.; Hyman BT.; Jarvik GP.; Abner E.; Jin LW.; Jun G.; Karydas A.; Kaye JA.; Kim R.; Kowall NW.; Kramer JH.; LaFerla FM.; Lah JJ.; Leverenz JB.; Levey AI.; Li G.; Lieberman AP.; Lunetta KL.; Lyketsos CG.; Marson DC.; Martiniuk F.; Mash DC.; Masliah E.; McCormick WC.; McCurry SM.; McDavid AN.; McKee AC.; Mesulam M.; Miller BL.; Miller CA.; Miller JW.; Morris JC.; Murrell JR.; Myers AJ.; O'Bryant S.; Olichney JM.; Pankratz VS.; Parisi JE.; Paulson HL.; Perry W.; Peskind E.; Pierce A.; Poon WW.; Potter H.; Quinn JF.; Raj A.; Raskind M.; Reisberg B.; Reitz C.; Ringman JM.; Roberson ED.; Rogaeva E.; Rosen HJ.; Rosenberg RN.; Sager MA.; Saykin AJ.; Schneider JA.; Schneider LS.; Seeley WW.; Smith AG.; Sonnen JA.; Spina S.; Stern RA.; Swerdlow RH.; Tanzi RE.; Thornton-Wells TA.; Trojanowski JQ.; Troncoso JC.; Van Deerlin VM.; Van Eldik LJ.; Vinters HV.; Vonsattel JP.; Weintraub S.; Welsh-Bohmer KA.; Wilhelmsen KC.; Williamson J.; Wingo TS.; Woltjer RL.; Wright CB.; Yu CE.; Yu L.; Garzia F.; Golamaully F.; Septier G.; Engelborghs S.; Vandenberghe R.; De Deyn PP.; Fernadez CM.; Benito YA.; Thonberg H.; Forsell C.; Lilius L.; Kinhult-Stählbom A.; Kilander L.; Brundin R.; Concari L.; Helisalmi S.; Koivisto AM.; Haapasalo A.; Dermecourt V.; Fievet N.; Hanon O.; Dufouil C.; Brice A.; Ritchie K.; Dubois B.; Himali JJ.; Keene CD.; Tschanz J.; Fitzpatrick AL.; Kukull WA.; Norton M.; Aspelund T.; Larson EB.; Munger R.; Rotter JI.; Lipton RB.; Bullido MJ.; Hofman A.; Montine TJ.; Coto E.; Boerwinkle E.; Petersen RC.; Alvarez V.; Rivadeneira F.; Reiman EM.; Gallo M.; O'Donnell CJ.; Reisch JS.; Bruni AC.; Royall DR.; Dichgans M.; Sano M.; Galimberti D.; St George-Hyslop P.; Scarpini E.; Tsuang DW.; Mancuso M.; Bonuccelli U.; Winslow AR.; Daniele A.; Wu CK.;  .; Peters O.; Nacmias B.; Riemenschneider M.; Heun R.; Brayne C.; Rubinsztein DC.; Bras J.; Guerreiro R.; Al-Chalabi A.; Shaw CE.; Collinge J.; Mann D.; Tsolaki M.; Clarimón J.; Sussams R.; Lovestone S.; O'Donovan MC.; Owen MJ.; Behrens TW.; Mead S.; Goate AM.; Uitterlinden AG.; Holmes C.; Cruchaga C.; Ingelsson M.; Bennett DA.; Powell J.; Golde TE.; Graff C.; De Jager PL.; Morgan K.; Ertekin-Taner N.; Combarros O.; Psaty BM.; Passmore P.; Younkin SG.; Berr C.; Gudnason V.; Rujescu D.; Dickson DW.; Dartigues JF.; DeStefano AL.; Ortega-Cubero S.; Hakonarson H.; Campion D.; Boada M.; Kauwe JK.; Farrer LA.; Van Broeckhoven C.; Ikram MA.; Jones L.; Haines JL.; Tzourio C.; Launer LJ.; Escott-Price V.; Mayeux R.; Deleuze JF.; Amin N.; Holmans PA.; Pericak-Vance MA.; Amouyel P.; van Duijn CM.; Ramirez A.; Wang LS.; Lambert JC.; Seshadri S.; Williams J.; Schellenberg GD.,"We identified rare coding variants associated with Alzheimer's disease in a three-stage case-control study of 85,133 subjects. In stage 1, we genotyped 34,174 samples using a whole-exome microarray. In stage 2, we tested associated variants (P < 1 × 10-4) in 35,962 independent samples using de novo genotyping and imputed genotypes. In stage 3, we used an additional 14,997 samples to test the most significant stage 2 associations (P < 5 × 10-8) using imputed genotypes. We observed three new genome-wide significant nonsynonymous variants associated with Alzheimer's disease: a protective variant in PLCG2 (rs72824905: p.Pro522Arg, P = 5.38 × 10-10, odds ratio (OR) = 0.68, minor allele frequency (MAF)cases = 0.0059, MAFcontrols = 0.0093), a risk variant in ABI3 (rs616338: p.Ser209Phe, P = 4.56 × 10-10, OR = 1.43, MAFcases = 0.011, MAFcontrols = 0.008), and a new genome-wide significant variant in TREM2 (rs143332484: p.Arg62His, P = 1.55 × 10-14, OR = 1.67, MAFcases = 0.0143, MAFcontrols = 0.0089), a known susceptibility gene for Alzheimer's disease. These protein-altering changes are in genes highly expressed in microglia and highlight an immune-related protein-protein interaction network enriched for previously identified risk genes in Alzheimer's disease. These genetic findings provide additional evidence that the microglia-mediated innate immune response contributes directly to the development of Alzheimer's disease.",2017,09,Nature genetics,49,9,1373-1384,,10.1038/ng.3916,28714976,#1471,Sims 2017,"",""
"Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing.",Kunkle BW.; Grenier-Boley B.; Sims R.; Bis JC.; Damotte V.; Naj AC.; Boland A.; Vronskaya M.; van der Lee SJ.; Amlie-Wolf A.; Bellenguez C.; Frizatti A.; Chouraki V.; Martin ER.; Sleegers K.; Badarinarayan N.; Jakobsdottir J.; Hamilton-Nelson KL.; Moreno-Grau S.; Olaso R.; Raybould R.; Chen Y.; Kuzma AB.; Hiltunen M.; Morgan T.; Ahmad S.; Vardarajan BN.; Epelbaum J.; Hoffmann P.; Boada M.; Beecham GW.; Garnier JG.; Harold D.; Fitzpatrick AL.; Valladares O.; Moutet ML.; Gerrish A.; Smith AV.; Qu L.; Bacq D.; Denning N.; Jian X.; Zhao Y.; Del Zompo M.; Fox NC.; Choi SH.; Mateo I.; Hughes JT.; Adams HH.; Malamon J.; Sanchez-Garcia F.; Patel Y.; Brody JA.; Dombroski BA.; Naranjo MCD.; Daniilidou M.; Eiriksdottir G.; Mukherjee S.; Wallon D.; Uphill J.; Aspelund T.; Cantwell LB.; Garzia F.; Galimberti D.; Hofer E.; Butkiewicz M.; Fin B.; Scarpini E.; Sarnowski C.; Bush WS.; Meslage S.; Kornhuber J.; White CC.; Song Y.; Barber RC.; Engelborghs S.; Sordon S.; Voijnovic D.; Adams PM.; Vandenberghe R.; Mayhaus M.; Cupples LA.; Albert MS.; De Deyn PP.; Gu W.; Himali JJ.; Beekly D.; Squassina A.; Hartmann AM.; Orellana A.; Blacker D.; Rodriguez-Rodriguez E.; Lovestone S.; Garcia ME.; Doody RS.; Munoz-Fernadez C.; Sussams R.; Lin H.; Fairchild TJ.; Benito YA.; Holmes C.; Karamujić-Čomić H.; Frosch MP.; Thonberg H.; Maier W.; Roshchupkin G.; Ghetti B.; Giedraitis V.; Kawalia A.; Li S.; Huebinger RM.; Kilander L.; Moebus S.; Hernández I.; Kamboh MI.; Brundin R.; Turton J.; Yang Q.; Katz MJ.; Concari L.; Lord J.; Beiser AS.; Keene CD.; Helisalmi S.; Kloszewska I.; Kukull WA.; Koivisto AM.; Lynch A.; Tarraga L.; Larson EB.; Haapasalo A.; Lawlor B.; Mosley TH.; Lipton RB.; Solfrizzi V.; Gill M.; Longstreth WT.; Montine TJ.; Frisardi V.; Diez-Fairen M.; Rivadeneira F.; Petersen RC.; Deramecourt V.; Alvarez I.; Salani F.; Ciaramella A.; Boerwinkle E.; Reiman EM.; Fievet N.; Rotter JI.; Reisch JS.; Hanon O.; Cupidi C.; Andre Uitterlinden AG.; Royall DR.; Dufouil C.; Maletta RG.; de Rojas I.; Sano M.; Brice A.; Cecchetti R.; George-Hyslop PS.; Ritchie K.; Tsolaki M.; Tsuang DW.; Dubois B.; Craig D.; Wu CK.; Soininen H.; Avramidou D.; Albin RL.; Fratiglioni L.; Germanou A.; Apostolova LG.; Keller L.; Koutroumani M.; Arnold SE.; Panza F.; Gkatzima O.; Asthana S.; Hannequin D.; Whitehead P.; Atwood CS.; Caffarra P.; Hampel H.; Quintela I.; Carracedo Á.; Lannfelt L.; Rubinsztein DC.; Barnes LL.; Pasquier F.; Frölich L.; Barral S.; McGuinness B.; Beach TG.; Johnston JA.; Becker JT.; Passmore P.; Bigio EH.; Schott JM.; Bird TD.; Warren JD.; Boeve BF.; Lupton MK.; Bowen JD.; Proitsi P.; Boxer A.; Powell JF.; Burke JR.; Kauwe JSK.; Burns JM.; Mancuso M.; Buxbaum JD.; Bonuccelli U.; Cairns NJ.; McQuillin A.; Cao C.; Livingston G.; Carlson CS.; Bass NJ.; Carlsson CM.; Hardy J.; Carney RM.; Bras J.; Carrasquillo MM.; Guerreiro R.; Allen M.; Chui HC.; Fisher E.; Masullo C.; Crocco EA.; DeCarli C.; Bisceglio G.; Dick M.; Ma L.; Duara R.; Graff-Radford NR.; Evans DA.; Hodges A.; Faber KM.; Scherer M.; Fallon KB.; Riemenschneider M.; Fardo DW.; Heun R.; Farlow MR.; Kölsch H.; Ferris S.; Leber M.; Foroud TM.; Heuser I.; Galasko DR.; Giegling I.; Gearing M.; Hüll M.; Geschwind DH.; Gilbert JR.; Morris J.; Green RC.; Mayo K.; Growdon JH.; Feulner T.; Hamilton RL.; Harrell LE.; Drichel D.; Honig LS.; Cushion TD.; Huentelman MJ.; Hollingworth P.; Hulette CM.; Hyman BT.; Marshall R.; Jarvik GP.; Meggy A.; Abner E.; Menzies GE.; Jin LW.; Leonenko G.; Real LM.; Jun GR.; Baldwin CT.; Grozeva D.; Karydas A.; Russo G.; Kaye JA.; Kim R.; Jessen F.; Kowall NW.; Vellas B.; Kramer JH.; Vardy E.; LaFerla FM.; Jöckel KH.; Lah JJ.; Dichgans M.; Leverenz JB.; Mann D.; Levey AI.; Pickering-Brown S.; Lieberman AP.; Klopp N.; Lunetta KL.; Wichmann HE.; Lyketsos CG.; Morgan K.; Marson DC.; Brown K.; Martiniuk F.; Medway C.; Mash DC.; Nöthen MM.; Masliah E.; Hooper NM.; McCormick WC.; Daniele A.; McCurry SM.; Bayer A.; McDavid AN.; Gallacher J.; McKee AC.; van den Bussche H.; Mesulam M.; Brayne C.; Miller BL.; Riedel-Heller S.; Miller CA.; Miller JW.; Al-Chalabi A.; Morris JC.; Shaw CE.; Myers AJ.; Wiltfang J.; O'Bryant S.; Olichney JM.; Alvarez V.; Parisi JE.; Singleton AB.; Paulson HL.; Collinge J.; Perry WR.; Mead S.; Peskind E.; Cribbs DH.; Rossor M.; Pierce A.; Ryan NS.; Poon WW.; Nacmias B.; Potter H.; Sorbi S.; Quinn JF.; Sacchinelli E.; Raj A.; Spalletta G.; Raskind M.; Caltagirone C.; Bossù P.; Orfei MD.; Reisberg B.; Clarke R.; Reitz C.; Smith AD.; Ringman JM.; Warden D.; Roberson ED.; Wilcock G.; Rogaeva E.; Bruni AC.; Rosen HJ.; Gallo M.; Rosenberg RN.; Ben-Shlomo Y.; Sager MA.; Mecocci P.; Saykin AJ.; Pastor P.; Cuccaro ML.; Vance JM.; Schneider JA.; Schneider LS.; Slifer S.; Seeley WW.; Smith AG.; Sonnen JA.; Spina S.; Stern RA.; Swerdlow RH.; Tang M.; Tanzi RE.; Trojanowski JQ.; Troncoso JC.; Van Deerlin VM.; Van Eldik LJ.; Vinters HV.; Vonsattel JP.; Weintraub S.; Welsh-Bohmer KA.; Wilhelmsen KC.; Williamson J.; Wingo TS.; Woltjer RL.; Wright CB.; Yu CE.; Yu L.; Saba Y.; Pilotto A.; Bullido MJ.; Peters O.; Crane PK.; Bennett D.; Bosco P.; Coto E.; Boccardi V.; De Jager PL.; Lleo A.; Warner N.; Lopez OL.; Ingelsson M.; Deloukas P.; Cruchaga C.; Graff C.; Gwilliam R.; Fornage M.; Goate AM.; Sanchez-Juan P.; Kehoe PG.; Amin N.; Ertekin-Taner N.; Berr C.; Debette S.; Love S.; Launer LJ.; Younkin SG.; Dartigues JF.; Corcoran C.; Ikram MA.; Dickson DW.; Nicolas G.; Campion D.; Tschanz J.; Schmidt H.; Hakonarson H.; Clarimon J.; Munger R.; Schmidt R.; Farrer LA.; Van Broeckhoven C.; C O'Donovan M.; DeStefano AL.; Jones L.; Haines JL.; Deleuze JF.; Owen MJ.; Gudnason V.; Mayeux R.; Escott-Price V.; Psaty BM.; Ramirez A.; Wang LS.; Ruiz A.; van Duijn CM.; Holmans PA.; Seshadri S.; Williams J.; Amouyel P.; Schellenberg GD.; Lambert JC.; Pericak-Vance MA.;  .;  .;  .;  .,"Risk for late-onset Alzheimer's disease (LOAD), the most prevalent dementia, is partially driven by genetics. To identify LOAD risk loci, we performed a large genome-wide association meta-analysis of clinically diagnosed LOAD (94,437 individuals). We confirm 20 previous LOAD risk loci and identify five new genome-wide loci (IQCK, ACE, ADAM10, ADAMTS1, and WWOX), two of which (ADAM10, ACE) were identified in a recent genome-wide association (GWAS)-by-familial-proxy of Alzheimer's or dementia. Fine-mapping of the human leukocyte antigen (HLA) region confirms the neurological and immune-mediated disease haplotype HLA-DR15 as a risk factor for LOAD. Pathway analysis implicates immunity, lipid metabolism, tau binding proteins, and amyloid precursor protein (APP) metabolism, showing that genetic variants affecting APP and Aβ processing are associated not only with early-onset autosomal dominant Alzheimer's disease but also with LOAD. Analyses of risk genes and pathways show enrichment for rare variants (P = 1.32 × 10-7), indicating that additional rare variants remain to be identified. We also identify important genetic correlations between LOAD and traits such as family history of dementia and education.",2019,03,Nature genetics,51,3,414-430,,10.1038/s41588-019-0358-2,30820047,#1473,Kunkle 2019,"",""
Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk.,Jansen IE.; Savage JE.; Watanabe K.; Bryois J.; Williams DM.; Steinberg S.; Sealock J.; Karlsson IK.; Hägg S.; Athanasiu L.; Voyle N.; Proitsi P.; Witoelar A.; Stringer S.; Aarsland D.; Almdahl IS.; Andersen F.; Bergh S.; Bettella F.; Bjornsson S.; Brækhus A.; Bråthen G.; de Leeuw C.; Desikan RS.; Djurovic S.; Dumitrescu L.; Fladby T.; Hohman TJ.; Jonsson PV.; Kiddle SJ.; Rongve A.; Saltvedt I.; Sando SB.; Selbæk G.; Shoai M.; Skene NG.; Snaedal J.; Stordal E.; Ulstein ID.; Wang Y.; White LR.; Hardy J.; Hjerling-Leffler J.; Sullivan PF.; van der Flier WM.; Dobson R.; Davis LK.; Stefansson H.; Stefansson K.; Pedersen NL.; Ripke S.; Andreassen OA.; Posthuma D.,"Alzheimer's disease (AD) is highly heritable and recent studies have identified over 20 disease-associated genomic loci. Yet these only explain a small proportion of the genetic variance, indicating that undiscovered loci remain. Here, we performed a large genome-wide association study of clinically diagnosed AD and AD-by-proxy (71,880 cases, 383,378 controls). AD-by-proxy, based on parental diagnoses, showed strong genetic correlation with AD (rg = 0.81). Meta-analysis identified 29 risk loci, implicating 215 potential causative genes. Associated genes are strongly expressed in immune-related tissues and cell types (spleen, liver, and microglia). Gene-set analyses indicate biological mechanisms involved in lipid-related processes and degradation of amyloid precursor proteins. We show strong genetic correlations with multiple health-related outcomes, and Mendelian randomization results suggest a protective effect of cognitive ability on AD risk. These results are a step forward in identifying the genetic factors that contribute to AD risk and add novel insights into the neurobiology of AD.",2019,03,Nature genetics,51,3,404-413,,10.1038/s41588-018-0311-9,30617256,#1454,Jansen 2019,"",""
GWAS on family history of Alzheimer's disease.,Marioni RE.; Harris SE.; Zhang Q.; McRae AF.; Hagenaars SP.; Hill WD.; Davies G.; Ritchie CW.; Gale CR.; Starr JM.; Goate AM.; Porteous DJ.; Yang J.; Evans KL.; Deary IJ.; Wray NR.; Visscher PM.,"Alzheimer's disease (AD) is a public health priority for the 21st century. Risk reduction currently revolves around lifestyle changes with much research trying to elucidate the biological underpinnings. We show that self-report of parental history of Alzheimer's dementia for case ascertainment in a genome-wide association study of 314,278 participants from UK Biobank (27,696 maternal cases, 14,338 paternal cases) is a valid proxy for an AD genetic study. After meta-analysing with published consortium data (n = 74,046 with 25,580 cases across the discovery and replication analyses), three new AD-associated loci (P < 5 × 10-8) are identified. These contain genes relevant for AD and neurodegeneration: ADAM10, BCKDK/KAT8 and ACE. Novel gene-based loci include drug targets such as VKORC1 (warfarin dose). We report evidence that the association of SNPs in the TOMM40 gene with AD is potentially mediated by both gene expression and DNA methylation in the prefrontal cortex. However, it is likely that multiple variants are affecting the trait and gene methylation/expression. Our discovered loci may help to elucidate the biological mechanisms underlying AD and, as they contain genes that are drug targets for other diseases and disorders, warrant further exploration for potential precision medicine applications.",2018,05,Translational psychiatry,8,1,99,,10.1038/s41398-018-0150-6,29777097,#1450,Marioni 2018,"",""
Genome-wide analysis of genetic predisposition to Alzheimer's disease and related sex disparities.,Nazarian A.; Yashin AI.; Kulminski AM.,"Alzheimer's disease (AD) is the most common cause of dementia in the elderly and the sixth leading cause of death in the United States. AD is mainly considered a complex disorder with polygenic inheritance. Despite discovering many susceptibility loci, a major proportion of AD genetic variance remains to be explained. We investigated the genetic architecture of AD in four publicly available independent datasets through genome-wide association, transcriptome-wide association, and gene-based and pathway-based analyses. To explore differences in the genetic basis of AD between males and females, analyses were performed on three samples in each dataset: males and females combined, only males, or only females. Our genome-wide association analyses corroborated the associations of several previously detected AD loci and revealed novel significant associations of 35 single-nucleotide polymorphisms (SNPs) outside the chromosome 19q13 region at the suggestive significance level of p < 5E-06. These SNPs were mapped to 21 genes in 19 chromosomal regions. Of these, 17 genes were not associated with AD at genome-wide or suggestive levels of associations by previous genome-wide association studies. Also, the chromosomal regions corresponding to 8 genes did not contain any previously detected AD-associated SNPs with p < 5E-06. Our transcriptome-wide association and gene-based analyses revealed that 26 genes located in 20 chromosomal regions outside chromosome 19q13 had evidence of potential associations with AD at a false discovery rate of 0.05. Of these, 13 genes/regions did not contain any previously AD-associated SNPs at genome-wide or suggestive levels of associations. Most of the newly detected AD-associated SNPs and genes were sex specific, indicating sex disparities in the genetic basis of AD. Also, 7 of 26 pathways that showed evidence of associations with AD in our pathway-bases analyses were significant only in females. Our findings, particularly the newly discovered sex-specific genetic contributors, provide novel insight into the genetic architecture of AD and can advance our understanding of its pathogenesis.",2019,01,Alzheimer's research & therapy,11,1,5,,10.1186/s13195-018-0458-8,30636644,#1455,Nazarian 2019,"",""
